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Farnesoid X receptor (FXR) is a ligand activated transcription factor belonging to 
the nuclear receptor superfamily and bile acids are its endogenous ligands. FXR is a 
critical regulator of the enterohepatic circulation of bile acids, lipid homeostasis, glucose 
metabolism, and tumor suppression in liver and intestine. Consequently, FXR has 
become a very promising therapeutic target for the prevention and/or treatment of 
cholestasis, hyperlipidemic disorders, metabolic syndrome, and liver and colon cancer. 
Studies suggest epigenetic mechanisms are critical for proper transcriptional induction 
of nuclear receptors. Likewise, evidence shows epigenetic mechanisms are responsible 
for modulating the tissue/cell-specific FXR expression in human colon cancer. However, 
how epigenetic mechanisms are involved in FXR induced transcription or tissue-specific 
FXR expression remains elusive. Understanding these mechanisms is crucial for future 
development of pharmacological modulators of FXR as well as understanding the full 
physiological roles of FXR. This dissertation was designed to elucidate epigenetic 
mechanisms involved in tissue-specific FXR induced gene transcription, orphan nuclear 
receptors critical for regulating FXR function, and epigenetic mechanisms responsible 
for FXR silencing in colon cancer. In specific aim 1, a genome-wide FXR binding assay 
was done in mouse liver and intestine. Specific aim 2 focuses on the role of the orphan 
nuclear receptor hepatocyte nuclear factor 4 alpha (HNF4 α) in regulating liver-specific 
functions of FXR. And finally, in specific aim 3, DNA methylation of FXR promoter was 
investigated as the mechanism responsible for FXR silencing in human colon cancer. In 
conclusion, genome-wide binding of FXR implicates novel epigenetic mechanisms and 
orphan nuclear receptors in regulating FXR function. Furthermore, this study indicates 
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that HNF4α is at least one orphan nuclear receptor capable of regulating FXR function 
in the liver. Findings from these first two aims succeeded in progressing drug 
development fields aimed at finding new FXR modulators for the treatment of multiple 
metabolic disorders by elucidating novel epigenetic mechanisms that may be 
investigated as therapeutic targets. Finally, FXR is at least partially down-regulated by 
DNA methylation in human colon cancer, suggesting a potential mechanism to be 





 It is a pleasure of mine to offer my deepest gratitude to all of those who have 
made the completion of this dissertation and PhD possible. Life often presents very few 
opportunities to publically thank those who contribute so extensively to your success as 
a professional, as well as your success as an individual. I would, therefore, like to take 
this opportunity now. To begin, I want to extend my deepest thanks to my mentor, Dr. 
Grace L. Guo, who was responsible for guiding my graduate research and education. 
Any success I obtained was largely due to the wonderful example and mentorship that 
Dr. Guo provided for me to emulate. Having the opportunity to learn from Dr. Guo has 
been an honor and a blessing. Dr. Guo has set such a high standard for me to strive to 
obtain, both professionally and personally. I will never be able to fully express the full 
magnitude of my gratitude towards Dr. Guo. I can only hope that I can sufficiently 
implement the things I have learned from her into my future career and life, and that I 
could, one day, be half the scientist Dr. Guo is.  
 I would also like to extend a special thanks to the members of my graduate 
committee, Drs. Bruno Hagenbuch, Xiao-bo Zhong, Brian Petroff, John Robertson, and 
Udayane Apte. Each of these members has offered valuable suggestions for my 
graduate research and education, and has helped guide me towards the successful 
completion of my dissertation. The different areas of expertise provided by each of 
these members allowed me to get a well-rounded, interdisciplinary training, which I 
know will be extremely valuable for my future career. Furthermore, I would like to 
express my appreciation for the committee guiding me in a relatively straightforward and 
direct manner, and not contributing any further difficulty to the graduate school process. 
vi 
 
I can honestly say that holding my semester committee meetings was almost a pleasure, 
and I realize that this process could have been much more extensive and difficult, and 
for that I am extremely thankful. 
 I would like to thank the department of Pharmacology, Toxicology & Therapeutics 
at the University of Kansas Medical Center, particularly members of the administrative 
staff, Rosa Meagher, Cody Tully, and Dorothy McGregor. These individuals have been 
extremely helpful in keeping me on track and have made the dissertation process as 
simple as they could possibly make it. I feel it is particularly important to thank these 
individuals because they do so much to make sure the students are successful in 
completing their PhDs in a timely manner, much of which I am sure we are unaware. 
Furthermore, I feel it is also important for me to thank a select few faculty members in 
the Pharmacology department, specifically Drs. Tom Pazdernik and Greg Reed. Both of 
these individuals took time out of their busy schedules on multiple occasions, despite 
having no obligation to do so, to help me in preparing for comprehensive exams, 
revising personal statements for job applications, preparing for job interviews, and 
providing encouragement for finishing my dissertation. The advice and suggestions they 
gave me proved to be extremely useful and valuable on multiple levels, and I want to 
make sure they are aware of my appreciation.  
 Furthermore, I would like to thank former and current members of the Guo 
laboratory, Dr. Erik Pacyniak, Noriko Esterly, Dr. Bo Kong, Dr. Guodong Li, Jessica 
Williams, Le Zhan, Dr. Manimaran Rengasamy, and Dr. Yan Zhu, who have been 
extremely helpful in teaching me new laboratory techniques, helping me complete 
course work, collaborating on projects, and/or providing friendship during my time as a 
vii 
 
graduate student. The Guo laboratory has been a joy to work in and the hard work and 
pleasant personalities of the lab members, and Dr. Guo herself, are largely why I chose 
to join this laboratory to complete my doctoral degree. For this, I would like to express 
my deepest thanks. Furthermore, I would like to give a special thanks to Dr. Steven Hart 
and Dr. Zhong’s laboratory for collaborating with me on multiple projects and providing 
expertise needed to complete these projects.  
 Next, I would like to thank my parents, John and Judy Pentlin, who have provided 
me with not only love, support, and encouragement I needed to successfully complete 
this process, but have single handedly been the greatest examples of hard work, 
perseverance, and character for me to emulate my life. My parents have always taught 
me that whatever I chose to do, to do it with all my might, which is largely why I strive so 
earnestly to be as successful as I can in whatever endeavor I embark. They have taught 
me to finish everything I begin, which has served particularly valuable for me during 
times when graduate school seemed too difficult to continue. The values and standards 
my parents instilled in me since youth are responsible for my decision to pursue a 
doctoral degree in science, and for my successfully completing this degree. For this, I 
thank you and I love you. 
 Of course, I have to thank my friends and family for giving me the stress and 
emotional release, encouragement, and support I inevitably needed throughout my time 
as a graduate student. Specifically, I would like to give heartfelt thanks to my aunt, 
Tracy Norrad, and my sister, Rene Bubanas, who have been such great friends and 
support system for me to lean on. Likewise, I would like to thank former and fellow 
graduate students from the department of Pharmacology, Toxicology, & Therapeutics at 
viii 
 
KUMC, Dr. Shary Shelton, Dr. Mary Shawgo, Colleen Flynn, Kristin Russell, Megan 
Roth, and Amanda Obaidat-Hays who have also helped provide support and friendship 
throughout my time at KUMC. These students provided advice and guidance in course 
work, job search, and writing of my dissertation, and I am extremely thankful for having 
them to defer to. I want also to extend my appreciation and thanks to my boyfriend, 
Robert Bailey, who has been unbelievably supportive and patient with my demanding 
schedule and hectic circumstances associated with the last two years of my studies. He 
has gone farther and beyond what is expected and I am perpetually grateful for the 
support he has given me. Furthermore, I would like to thank my closest friends, Heather 
Gunn and Tammy West, for helping encourage, support, and influence me in such a 
profound way. Ultimately, the influence of all of these individuals has made the 
completion of my doctoral degree possible. 
 Finally, but certainly not least, I would like to thank God. I firmly believe my 
success in graduate school and in life has not been by my efforts alone, but a blessing 
and gift from God. At the risk of sounding overly dramatic, I strongly believe pursuing a 
doctoral degree in science was something I was directed towards and it has taken 









List of Figures and Legends………..………………………………………………..… ….xv 
List of Abbreviations… …………………………………………………………….……...xvii 
Chapter 1: Introduction and Background………………………………… ……………... 1 
1.1: Introduction to Farnesoid X Receptor…………………………...……………… 1  
1.1.1: Role of FXR in the enterohepatic circulation of bile acids……....…. 4  
1.1.2: Role of FXR in lipid and glucose metabolism.……..………………... 9   
1.1.3: Targeting FXR for pharmacotherapy……………….………………. 12  
1.2: The Role of Epigenetic Mechanisms in Regulating Nuclear Receptor 
Function……………………………………………………………………………..… 15  
1.2.1: Overview of histone modifications associated with active/repressed 
gene transcription..................................................................................... 16  
1.2.2: Overview of co-factors and pioneer factors that are involved in 
nuclear receptor-mediated transcriptional regulation….………….…….... 18  
1.3: Introduction to HNF4α in Regulating Liver Homeostasis….…………….....  20  
x 
 
1.4: Introduction to Role of FXR in Colon Cancer Progression……….………… 21 
1.5: Introduction to DNA Methylation in Cancer……………………………...…… 23 
1.6: Concluding Introductory Remarks................................................................ 24 
Chapter 2: Statement of Purpose……………………………………………….……….. 26  
2.1: Significance……………………………………………………………………… 26 
2.1.1: A comprehensive genome-wide view of FXR function is essential for 
understanding tissue-specific functions of FXR and for development of 
therapeutic modulators of FXR…………………………………....………... 26 
2.1.2: Orphan nuclear receptors, namely HNF4α, and epigenetic 
mediators may help to regulate FXR function…………………………..… 28 
2.1.3: Understanding the role of FXR and the mechanism of FXR down-
regulation in colon cancer could provide valuable information for targeting 
FXR for the prevention, treatment, and/or diagnosis of colon cancer….. 29 
2.2: Overall Hypothesis…………………….…..……………………….…………… 30 
2.3: Specific Aims…………………………………………………………………….. 31 
2.3.1: Specific aim 1: identify direct genome-wide FXR binding sites in 
liver and intestine………..………………………………………...…………. 31 
2.3.2: HNF4α functions to co-regulate FXR function in the liver………... 31 
xi 
 
2.3.3: FXR is down-regulated in human colon cancer by DNA methylation 
of the FXR promoter…………………………………………...…………..… 32 
Chapter 3: Materials and Methods………………………..……………………………... 34 
3.1 Animals and Treatment…………………..……………………………………… 34 
  3.1.1 Animals used for genome-wide binding studies and ChIP-qPCR... 34 
  3.1.2: Animals for co-IP assays…………………………………….……..... 34 
  3.1.3: Animals for FXR expression…………...…………………………….. 35 
3.2: ChIP-Sequencing…………………………………..…………………………… 35 
  3.2.1: Chromatin immunoprecipitation for sequencing………...………… 35 
3.2.2: Sequencing analysis of ChIP DNA……………………………...….. 38 
3.2.3: ChIP-Seq analysis of FXR and HNF4α in mouse livers………….. 39 
3.2.4: Motif identification………………………...…………………………... 39 
3.2.5: Pathway analysis…………...………………………………………… 40 
 3.3: ChIP-qPCR assays……………………………………………………………… 40 
 3.4: Co-IP……………………………………………………………………………… 41 
 3.5: Cell Culture………………………………………………………………………. 44 




3.5.2: Colon cancer cell lines and FXR expression……...……………….. 46 
3.5.3: Azacytidine treatment………….………………….………………….. 46 
 3.6: Human Colon Cancer Samples and FXR Expression………………………..47 
 3.7: MeDIP Assay…………………………………………………………………….. 48 
 3.8: Bisulfite Sequencing…………………………………………………………….. 50 
 3.9: SiRNA Knockdown…………………………………...…………………………. 53 
 3.10: RNA Extraction and Real-Time qPCR………………..……..………………. 54 
 3.11: Genomic DNA Extraction for MeDIP and Bisulfite Sequencing…...……… 54  
 3.12: Western Blot……………………….…………………………………………… 55 
 3.13: Statistical Analysis……………………………………………..…………….…56 
Chapter 4: Genome-wide Tissue Specific FXR Binding in Mouse Liver and 
Intestine……………………………………………… .……………………………………… 57 
 4.1: Abstract……………………………………………………………….………….. 57 
 4.2: Introduction……………………………………………………………………… 58 
 4.3: Results…………………………………………………………………………… 60 
4.3.1: Determine the optimal time point of FXR/DNA binding in vivo 
following ligand treatment…………………………………………………… 60 
4.3.2: Validation of FXR binding sites discovered by ChIP-seq…….…… 63 
xiii 
 
4.3.3: Analysis of genome-wide FXR binding sites in liver and 
intestine………………………………………………………………………... 65 
4.3.4: Novel FXR binding sites revealed by ChIP-Seq…………………… 73 
4.3.5: Motif analysis of FXR binding sites…………………………………. 76 
4.3.6: Biological pathway analysis…………………………….……………. 76 
4.4: Concluding Remarks…………………………………………………..……….. 80 
Chapter 5: FXR and HNF4 α Interact to Cooperatively Regulate Gene Transcript ion 
in the Liver……… …………………………………………………………………………… 85 
 5.1: Abstract………………………………………………………………………….. 85 
 5.2: Introduction………………………………………………………………………. 86 
5.3: Results………………………………………………………………………….… 88 
 5.3.1: ChIP-sequencing…………………………………………………….... 88 
  5.3.2: ChIP-qPCR…………………………………………………………….. 92  
5.3.3: Co-IP…………………………………………………………………… 96 
5.3.4: Luciferase activity………………………..………………………….… 96 
5.4: Concluding Remarks……………………………………………………………. 99 
Chapter 6: DNA Methylation as a Mechanism of FXR Do wn-regulation in Human 
Colon Cancer… …………………………………………………………………………..... 104 
xiv 
 
6.1 Abstract………………………….………………………………………………. 104 
6.2 Introduction…………………………………………………………………....… 105 
6.3 Results…………………………………………………………………………… 107 
 6.3.1 FXR expression in intestinal carcinogen mouse model…………...107   
 6.3.2 FXR expression in human colon cancers………….………………. 108  
 6.3.3 Azacytidine treatment………………………………………………... 111 
6.3.4 MeDIP analysis……………………………………………………….. 114 
6.3.5 Bisulfite treatment……………………………………………………..115 
6.3.6 SiRNA knockdown….………………………………………………... 118 
6.4 Concluding Remarks.…………………………………………………….……. 119 
Chapter 7: Discussion and Conclusions…… ……………………………………….... 128 
7.1 General Discussion…………………………………………………………….. 128 
7.2 Overall Conclusions……………………………………………………………. 129 
7.2.1 Genome-wide binding of FXR in liver and intestine………………. 129 
7.2.2 FXR and HNF4α interact to cooperatively regulate gene transcription 
in the liver..………..…………………………………………………………. 131  
7.2.3 DNA methylation as a mechanism of FXR down-regulation in human 
colon cancer…………………………………………………………………. 133 
7.3 Concluding Remarks…………………………………………………………… 135 
Chapter 8: Future Directions……………………………………………………………..137 
xv 
 
List of Figure and Tables  
Figure 1. The classical protein structure of FXR………………………………………...…. 2 
Figure 2. FXR and disease………….……………………………………………….…...…... 5  
Figure 3. Enterohepatic circulation of bile acids………………………………………..…... 6 
Figure 4. Chemical structures of semi-synthetic and synthetic FXR modulators……… 14 
Figure 5. FXR antibody specificity……………………………………………………… 36-37 
Figure 6. Predicted CpG islands within the FXR (NR1H4) gene……………………. 51-52 
Figure 7. Initial Validation of FXR binding to known FXRREs by ChIP-qPCR…….. 61-62 
Figure 8. Total FXR binding sites in liver and intestine…………………………….… 66-67 
Figure 9. Histogram of novel FXR binding sites within known FXR target genes, Nr0b2  
and Ostb…………………………………………………………………………………... 69-70 
Figure 10. Distribution of total FXR binding sites relative to TSSs and intron binding of  
FXR………………………………………………………………………………………… 71-72 
Figure 11. Histogram of novel FXR binding sites within Nr1i2, Osta, and Slc10a1.. 74-75 
Figure 12. Motif analysis………………………………………………………….……… 77-78 
Figure 13. Genome-wide binding of FXR and HNF4α in mouse liver…….………… 89-90 
Figure 14. Histogram of binding of FXR and HNF4α to Nr0b2 (Shp) gene and ChIP- 
qPCR analysis…………………………………………………………………………….. 94-95 
Figure 15. Co-IP of FXR and HNF4α and luciferase assays………………………....97-98 
Figure 16. Relative expression of FXR and FXR target genes in APCmin mice, human  
colon cancer samples, and human colon cancer cell lines…………………...…... 108-109 
xvi 
 
Figure 17. Relative expression of FXR in human colon cancer cell lines treated with  
a DNMT inhibitor and MeDIP analysis of FXR promoter CpG island………….… 112-113 
Figure 18. Relative expression of FXR and bisulfite sequencing analysis of FXR  
promoter CpG island in colon cancer cell lines…………………………………….. 116-117 
Figure 19. SiRNA knockdown of DNMT 1 and 3B…………………….………….... 120-121 
Figure 20. Schematic of FXR silencing in human colon cancer……………...…... 126-127 
Table 1. Primers for ChIP-qPCR assays…………………….……………………….... 42-44 
Table 2. KUMC cancer center biospecimen pathology reports summary……….…...… 49 
Table 3. Real-time PCR primers……………………………………..……………………... 55 
Table 4. Previously reported FXR binding sites detected by ChIP-Seq………………... 63 
Table 5. List of genes validated after the ChIP-seq assay in the liver………………….. 64 
Table 6. List of genes validated after the ChIP-seq assay in the intestine…………….. 64 
Table 7. Validation of ChIP-seq: percentage of ChIP-seq binding sites confirmed by  
ChIP-qPCR………………………………………………………………………………….… 65 
Table 8. Pathways enriched with FXR binding 2 kb up-stream of genes in liver……… 79 
Table 9. Pathways enriched with FXR binding 2 kb up-stream of genes in intestine…. 81 
Table 10. Pathways enriched by both FXR and HNF4α binding in mouse liver………. 92 
Table 11. List of FXR and HNF4α shared target genes categorized within complement 
and coagulation cascades…………………………………………………………………... 93 
Table 12. FXR and HNF4α binding sites from ChIP-seq analysis………………….…... 96 
Table 13. FXR expression in colon cancer cell lines after azacytidine treatment……. 111 
xvii 
 
List of Abbreviations  
APC: adenomatous polyposis coli 
APOA-I: apolipoprotein A-I 
APOC-II: apolipoprotein C-II 
APOC-III: apolipoprotein C-III 
ASBT: apical sodium dependent bile salt transporter 
AZA: azacytidine 
BAAT: bile acid-CoA: amino acid N-acyltransferase  
BSEP: bile salt export pump 
CA: cholic acid 
CAR: constitutive androstane receptor 
CARM-1: coactivator associated arginine methyl transferase-1 
CDCA: chenodeoxycholic acid 
ChIA-PET: chromatin interaction analysis with paired-end tag sequencing 
ChIP: chromatin immunoprecipitation 
ChIP-qPCR: chromatin immunoprecipitation followed by quantitative PCR 
ChIP-Seq: chromatin immunoprecipitation followed by massive parallel sequencing 
Co-IP: co-immunoprecipitation 
COL1A2: collagen-α2 
CYP7A1: cytochrome p450 7A1; cholesterol 7 alpha-hydroxylase 
CYP8B1: cytochrome p450 8B1; sterol 12-alpha-hydroxylase 
xviii 
 
CYP3A4: cytochrome p450 3A4 
DBD: DNA binding domain 
DCA: deoxycholic acid 
DNMT: DNA methyltransferase 
DR-1: direct repeat separated by one nucleotide 
ER-2: everted repeat separated by two nucleotides 
ERα: estrogen receptor alpha 
FGF 15/19: fibroblast growth factor 15/19 
FGFR4: fibroblast growth factor receptor 4 
FOXA1: foxhead box protein A1 
FXR: farnesoid X receptor 
FXRRE: FXR response element 
H3K4: histone 3 lysine 4 
H3K4me: histone 3 lysine 4 monomethylation 
H3K9: histone 3 lysine 9 
H4K20: histone 4 lysine 20 
H3K27: histone 3 lysine 27  
H3K36: histone 3 lysine 36 
HAT: histone acetyltransferases 
HCC: hepatocellular carcinoma 
HNF4α: hepatocyte nuclear factor alpha 
xix 
 
IBABP: ileal bile acid binding protein 
ICP: intrahepatic cholestasis of pregnancy 
IGB: integrated genome browser 
IP: immunoprecipitation 
IR-1: inverted repeat separated by one nucleotide 
L-FABP: liver fatty acid binding protein 
LBD: ligand binding domain 
LCA: lithocholic acid 
LPL: lipoprotein lipases 
LRH-1: liver receptor homolog 1 
MACS: model-based analysis of ChIP-seq 
MeDIP: methylated DNA immunoprecipitation 
mEH: microsomal epoxide hydrolase 
MEME: multiple em for motif elicitation 
MRP2: multidrug resistance protein 2 
NAFLD: non-alcoholic fatty liver disease 
NCOR: nuclear corepressor 
NFκB: nuclear factor kappa B 
NR0B2: nuclear receptor subfamily 0, group B, member 2 
NR1H4: nuclear receptor subfamily 1, group H, member 4 
NR1I2: nuclear receptor subfamily 1, group I, member 2 
xx 
 
NTCP: Na/taurocholate cotransporting polypeptide 
OATP: organic anion transporting polypeptides 
OST α: organic solute transporter alpha 
OST β: organic solute transporter beta 
PCR: polymerase chain reaction 
PGC1α: peroxisome-proliferator-receptor (PPAR)-gamma-coactivator-1α  
PRMT-1: protein arginine methyl transferase-1 
PXR: pregnane X receptor 
RXRα: retinoic X receptor alpha 
RNA Pol II: RNA polymerase II 
SHP: small heterodimer protein 
SMRT: silencing mediator of retinoic acid and thyroid hormone receptor 
SRC-1: coactivators steroid receptor coactivators 1 
SREBP-1c: sterol regulatory element-binding protein 1c 
TG: triglyceride 
TF: transcription factor 
TNFα: tumor necrosis factor alpha 
TSS: transcription start site 




Chapter 1: Introduction and Background 
 
1.1: Introduction to Farnesoid X Receptor (FXR): 
Farnesoid X Receptor (FXR) is a ligand activated nuclear receptor belonging to 
the nuclear receptor superfamily. FXR was first identified in yeast as an orphan nuclear 
receptor capable of heterodimerizing with retinoid X receptor alpha (RXRα) and 
transcriptionally responding to RXR ligands (Seol et al., 1995). A mouse homologue of 
FXR was subsequently cloned and found to respond to supraphysiological 
concentrations of farnesol, an intermediate of the mevalonate biosynthetic pathway, 
whereby it obtained its name (Forman et al., 1995). Shortly after being cloned, bile acids 
were identified as endogenous ligands of FXR, and therefore, FXR became an adopted 
orphan nuclear receptor (Makishima et al., 1999; Parks et al., 1999; Wang et al., 1999).  
The FXR protein is encoded by the gene NR1H4 and is highly expressed in the 
liver, intestine, kidney, and adrenal gland, with low expression being found in the heart, 
and adipose tissues (Zhang et al., 2003). The FXR protein exhibits the classical nuclear 
receptor structure homology consisting of a highly conserved DNA binding domain 
(DBD), a C-terminal region containing a ligand binding domain (LBD) and a ligand-
dependent transactivation domain, AF2, and a ligand-independent transactivation 
domain, AF1, at the N-terminus (Figure 1 ; Modica et al., 2010).  
The DNA binding domain contains two Zn2+ finger motifs needed for DNA binding 
and dimerization with RXRα (reviewed by Olefsky, 2001; Pellicciari et al., 2005). The 
ligand binding domain contains a hydrophobic pocket critical for the binding of bile acids.  
 








The AF2 and AF1 domains are responsible for mediating interactions with co-regulatory 
proteins (reviewed by Modica et al., 2010). 
FXR is classified as a type II nuclear receptor which are different from type I, III, 
and IV nuclear receptors by localizing mainly to the nucleus and initiating gene 
transcription predominantly as a heterodimer with RXRα. Type II nuclear receptors 
consist mainly of subfamily 1 members of the nuclear receptor superfamily. Despite 
FXR’s classification as a type II nuclear receptor, whether nuclear translocation of FXR 
occurs upon ligand binding is not clear. In the best accepted scenario, FXR 
constitutively sits on FXR response elements (FXRREs) within target genes as a 
heterodimer with RXRα. In the absence of bile acids, the FXR-RXRα dimer interacts 
with corepressors and represses gene transcription. Upon binding of bile acids, the 
FXR-RXRα heterodimer releases corepressors and recruits coactivators, and 
subsequently initiates transcription of FXR target genes (reviewed by Modica et al., 
2010). In an alternative and less characterized scenario, FXR is sequestered either in 
the cytosol or nucleus, or both, and binding of bile acids induces access of FXR to the 
chromatin, heterodimerization with RXRα, enrichment of FXR to FXRREs located in 
target genes, recruitment of coactivators, and initiation of target gene transcription. 
Existing evidence suggests that FXR may function in both of these manners (Chong et 
al., 2010; Fang et al., 2008; Rizzo et al., 2005; Thomas et al., 2010). Nevertheless, the 
most well characterized FXRRE is an inverted repeat (A/GGG/TCA) separated by one 
nucleotide (IR-1). 
As mentioned, FXR is highly expressed in liver and intestine and its main 
characterized role is regulating the enterohepatic circulation of bile acids. However,
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recent studies have elucidated roles of FXR in lipid and glucose metabolism and have 
suggested FXR as a potential therapeutic target for the treatment of cholestasis,  
hyperlipidemia, type II diabetes, non-alcoholic fatty liver disease (NAFLD), and 
gastrointestinal cancers (Figure 2 ). FXR’s role in all of these processes will be reviewed 
below. 
 
1.1.1: Role of FXR in the enterohepatic circulation  of bile acids.  
The original generation of FXR knockout (KO) mice was associated with elevated 
serum bile acid levels and changes in gene expression of genes involved in bile acids 
synthesis, transport, and metabolism revealing the significant role FXR plays in 
regulating bile acid homeostasis (Kok et al., 2003; Sinal et al., 2000). Since then, FXR 
has been determined to be a master regulator of the enterohepatic circulation of bile 
acids (Figure 3 ). To begin, bile acids are synthesized in the liver through the enzymatic 
conversion of cholesterol to primary bile acids, cholic acid (CA) and chenodeoxycholic 
acid (CDCA). There are multiple enzymatic pathways that convert cholesterol to primary 
bile acids within different hepatic cellular compartments. However, the main bile acid 
synthesis pathway includes the enzymatic conversion of cholesterol to equal ratio of CA 
and CDCA by the rate-limiting enzyme CYP7A1, located on the endoplasmic reticulum 
membrane, and is termed the “classical pathway” (Russell, 2003). Primary bile acids are 
further metabolized by conjugation to glycine or taurine (Russell and Setchell, 1992; 
Sjovall, 1959; Vlahcevic et al., 1999). Bile acids are mainly transported out of the liver 
and into the bile duct through the ATP-dependent bile salt export pump (BSEP;  
 
Figure 2: FXR and disease . FXR has been shown to 
several diseases (listed below)





attenuate the development of 










Gerloff et al., 1998; Noe et al., 2002). Di-anionic conjugated bile acids are not 
substrates for BSEP and can be effluxed through the cannalicular multidrug resistance 
protein 2 (MRP2; Keppler et al., 1997; St-Pierre et al., 2001). 
Bile acids flow from the bile duct into the gall bladder where they are stored. After 
a meal, the endocrine cells of the intestinal mucosa release cholecystokinin stimulating 
the gall bladder to contract and releasing bile acids into the intestinal lumen of the 
duodenum (Hofmann, 1999). Bile acids aid in the emulsification and absorption of 
ingested lipids and lipid soluble vitamins in the small intestine and are reabsorbed via 
active transport in the distal ileum (Ridlon et al., 2006). Enterocyte uptake of conjugated 
bile acids is mediated via the apical sodium dependent bile salt transporter (ASBT; 
Geyer et al., 2006; Shneider et al., 1995; Wong et al., 1994). As bile acids enter 
enterocytes of the ileum, they are retrieved intracellularly by the ileal bile acid binding 
protein (IBABP; Kramer et al., 2001; Trauner and Boyer, 2003). IBABP is involved in 
intracellular trafficking of bile acids by retrieving them from the apical membrane and 
delivering them to either nuclear compartment or basolateral membrane. IBABP is 
suggested to help prevent bile acid induced toxicity to intestinal cells (Fang et al., 2007). 
Bile acids can bind to and activate intracellular FXR within enterocytes of the distal 
ileum. FXR then initiates transcription of target genes by forming a homodimer or 
heterodimer with RXRα and binding DNA response elements within regulatory regions 
of response genes.   
Intestinal activation of FXR induces the expression of fibroblast growth factor 
(FGF) 15 in mice, or FGF19 in humans, IBABP, and efflux transporters organic solute 
transporters (OST) α and β (Dawson et al., 2005; Grober et al., 1999; Inagaki et al., 
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2005; Landrier et al., 2006). OSTα and OSTβ heterodimerize at the basolateral 
membrane of enterocytes and efflux bile acids from enterocytes into the portal 
circulation (Dawson et al., 2005; Landrier et al., 2006). Nearly 95% of the primary bile 
acids are absorbed by ileal enterocytes via passive diffusion or facilitated and active 
transport. However, 5% of conjugated primary bile acids continue in route towards the 
colon where colonic bacteria can metabolize primary bile acids to the secondary bile 
acids, lithocholic acid (LCA) and deoxycholic acid (DCA). DCA is hydrophobic and can 
be readily reabsorbed by colonic epithelium by passive diffusion and/or active transport 
via similar mechanisms described above, and is transported back to the liver. DCA is 
mainly reabsorbed and accumulates in the enterohepatic bile acid pool where as LCA is 
excreted in the feces (Cowen et al., 1975; Ridlon et al., 2006).   
 FGF15/19 is synthesized in the ileum of the small intestine and is a secreted 
peptide that travels via the portal circulation or lymphatics back to the liver (Inagaki et al., 
2005). FGF15/19 selectively binds to the basolateral transmembrane protein FGF 
receptor 4 (FGFR4) in the liver. FGFR4 has tyrosine kinase activity and is suggested to 
signal through MAP kinase pathways (Xie et al., 1999). The ultimate binding of 
FGF15/19 to FGFR4 results in the inhibition of CYP7A1/Cyp7a1 transcriptional 
activation and down-regulation in bile acid synthesis (Inagaki et al., 2005). 
As mentioned, bile acids absorbed in the intestines by either passive diffusion or 
through the uptake transporter ASBT are bound intracellularly to IBABP and then 
transported into portal circulation via OSTα/β (Grober et al., 1999; Kramer et al., 2001; 
Landrier et al., 2006). In the portal circulation, bile acids bound to plasma protein 
albumin are circulated back to the liver where they dissociate from albumin (Berk et al., 
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1987; Roda et al., 1982) and are actively taken up into the hepatocyte mainly by the 
uptake transporter Na/taurocholate cotransporting polypeptide (NTCP; Hagenbuch et al., 
1991; Meier, 1995; Schroeder et al., 1998). Bile acids have also been reported to be 
taken up into hepatocytes through sodium independent mechanisms (Kouzuki et al., 
1998; Maglova et al., 1995; Yamaguchi et al., 2006) including uptake by organic anion 
transporting polypeptides (OATPs) 1B1 and 1B3 (Yamaguchi et al., 2006). It has also 
been suggested that microsomal epoxide hydrolase (mEH) mediates sodium dependent 
bile acid uptake (Von Dippe et al., 1993; von Dippe et al., 1996), however, the 
mechanism and significance of this is controversial (Hagenbuch et al., 1996). 
Intracellular bile acids in hepatocytes bind to liver fatty acid binding protein (L-FABP) 
which facilitates bile acid trafficking to the cannalicular membrane (Martin et al., 2005).  
Hepatic intracellular bile acids bind to and activate FXR which homodimerizes or 
heterodimerizes with RXRα and induces expression of FXR target genes, including 
small heterodimer partner (SHP) and BSEP (Goodwin et al., 2000). SHP is a universal 
inhibitory factor that inhibits liver receptor homolog 1 (LRH-1) induced transcription of 
CYP7A1 and CYP8B1 (Goodwin et al., 2000). Therefore, SHP up-regulation in the liver, 
in cooperation with FGF-15/19 from the intestine, results in an additive down-regulation 
of bile acid synthesis (Goodwin et al., 2000; Inagaki et al., 2005). In essence, bile acids 
reabsorbed in the intestines function to feedback inhibit synthesis of bile acids in the 
liver. 
 
1.1.2: Role of FXR in lipid and glucose metabolism.  
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As mentioned, FXR has been shown to play a role in regulating other metabolic 
pathways aside for its role in bile acid homeostasis, including lipid and glucose 
metabolism. Studies in mice have shown that FXR activation has beneficial effects on 
lipid and glucose parameters within disease mouse models revealing its potential as a 
target for the treatment of diseases such as hyperlipidemia, fatty liver, and diabetes 
(Figure 2 ).  
Shortly after discovering FXR as a transcriptional regulator of bile acid synthesis 
and metabolism, it was speculated that FXR may play a role in lipid metabolism. It was 
subsequently shown that mice and rats treated with a synthetic FXR agonist, GW4064, 
had decreased plasma triglyceride (TG) levels (Claudel et al., 2003; Maloney et al., 
2000; Zhang et al., 2006). Next, FXR was shown to negatively regulate the transcription 
of sterol regulatory element-binding protein 1c (SREBP-1c), a transcription factor (TF) 
essential for stimulating fatty acid synthesis (Watanabe et al., 2004). In a mouse model 
of obesity and type 2 diabetes, the KK-A(y) mouse, FXR activation resulted in a 
reduction of liver and serum TG levels and very low density lipoprotein secretion 
through FXR-induced transcription of SHP (Watanabe et al., 2004). It was further 
elucidated that SHP can interfere directly with liver X receptor’s  (LXR) ability to bind to 
SREPB-1c promoter and induce transcription leading to an overall suppression of 
lipogenesis as a consequence of FXR activation (Watanabe et al., 2004). In addition, 
FXR can also directly modulate transcription of genes involved in TG clearance by 
inducing genes responsible for activating lipoprotein lipases (LPL) and TG hydrolysis, 
such as apolipoprotein C-II (APOC-II) (Kast et al., 2001), and repressing transcription of 
genes involved in LPL inhibition, such as apolipoprotein  C-III (APOC-III; Claudel et al., 
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2003). Therefore, FXR has become a potential therapeutic target for the treatment of 
hyperlipidemic disorders. 
In addition, FXR’s role in glucose metabolism has become a more recent field of 
interest when studies showed that altering bile acid profiles modified glucose 
parameters in models of diabetes (Staels and Kuipers, 2007) suggesting the regulation 
of bile acid synthesis and glucose metabolism may be linked. It was then shown that a 
rat model of diabetes had decreased liver expression of FXR with a correlating increase 
in bile acid pool size, and insulin administration returned FXR  levels to normal (Duran-
Sandoval et al., 2004). These results indicate glucose directly regulates the expression 
of FXR. Furthermore, FXR has also been shown to regulate insulin-sensitivity. This was 
seen in FXR KO mice which have impaired glucose-tolerance and insulin sensitivity 
(Cariou et al., 2006; Ma et al., 2006; Zhang et al., 2006). The effects of FXR on insulin 
sensitivity are not well elucidated, but have been suggested to be mediated by FXRs 
induction of FGF15/19 (Kir et al., 2011). However, FXR has also been shown to directly 
repress the transcription of rate-limiting enzymes involved in gluconeogenesis via the 
FXR-SHP transcriptional pathway (Ma et al., 2006; Zhang et al., 2006). Although more 
work is needed to further characterize the comprehensive roles of FXR in glucose 
metabolism, there are promising data suggesting FXR agonists as a treatment option 
for patients with type II diabetes. 
Because FXR has emerged as a major regulator of several metabolic processes 
including cholesterol, bile acid, lipid and glucose metabolism, research targeting FXR as 
a therapeutic option for the treatment of disorders such as cholestasis, hyperlipidemia, 
and metabolic syndrome should be further pursued. In order to accomplish this, though, 
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a better understanding on how FXR induces transcription of target genes on a genome-
wide and tissue-specific scale is needed. 
 
1.1.3: Targeting FXR for pharmacotherapy.  
Over the last two decades, FXR’s role in regulating multiple metabolic pathways 
has become increasingly intriguing for the drug development field to design FXR 
modulators for the treatment and/or prevention of several diseases. FXR’s role in 
regulating the synthesis, transport, and metabolism of bile acids has allowed it to be a 
potential target for the treatment of cholestasis and hypercholesterolemia. Likewise, as 
was described above, FXR role in negatively regulating genes involved in lipogenesis 
and gluconeogenesis suggest it as a promising therapeutic target for disorders 
associated with metabolic syndrome. Finally, though still poorly understood, FXR has 
been suggested to suppress the development of colon and liver cancers (Kim et al., 
2007; Modica et al., 2008; Yang et al., 2007), and therefore has become a possible 
target for the prevention and/or treatment for these cancers.  
Using bile acids for targeting FXR as a therapeutic agent has become less 
desirable largely due to toxicities associated with elevated bile acid levels, as well as 
other adverse side effects such a pruritus, a condition involving itching of the skin due to 
elevated systemic bile acid levels (Varadi, 1974). Therefore, synthetic and semi-
synthetic FXR agonists have been development in order to enhance selective activation 
of FXR (Figure 4, obtained from PubChem Compound). Semi-synthetic FXR 
modulators have been developed by chemically modifying the steroid nucleus backbone 
of bile acids. An example of this is a 6α-ethyl derivative of DCA (6α-ECDCA, INT-747), 
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which is currently in phase II clinical trials for the treatment of primary biliary cirrhosis 
(Intercept Pharmaceuticals, NCT00550862). In addition, stilbene derivatives of synthetic 
retinoids were developed for selective activation of FXR, leading to the development of 
GW4064 (Maloney et al., 2000), a potent and selective activator of FXR with relatively 
low toxicity and, unfortunately, low bioavailability (Kim et al., 2007). This led to the 
development of a more bioavailable FXR agonist, WAY-362450, in-licensed by Exelixis, 
intended for the treatment of hyperlipidemia (Evans et al., 2009; Flatt et al., 2009). 
Likewise, synthetic biaryl cinnamate derivates of the benzopyran backbone, such as 
fexaramine and fexarine, were developed as selective and potent FXR agonists 
(Downes et al., 2003). However, all of these synthetic FXR agonists seem to activate 
FXR target genes in different manners suggesting that these synthetic ligands may act 
as gene-selective FXR modulators (Downes et al., 2003). In addition to synthetic 
modulators, emerging evidence has shown natural products as being capable of 
activating FXR, such as cafestol and green tea catechins (Ricketts et al., 2007) 
unpublished data from Guo lab), which also may serve as potential therapeutic options 
for treatment and/or prevention of disease, namely intestinal disease such as irritable 
bowel disorder, ulcerative colitis, and colon cancer. 
However, as we know from the use of modulators of other nuclear receptors, 
such as agonists for estrogen receptor and the peroxisome proliferator family of 
receptors, many adverse health effects can be associated with targeting nuclear 
receptors for the treatment of human disease. In the case of FXR, little is known about 




Figure 4: Chemical structures of semi-synthetic and  synthetic FXR modulators 







effects have been noted and/or speculated. Therefore, much research is needed in 
understanding the genome-wide, tissue-specific, and systemic effects of FXR activation. 
This is necessary so that FXR modulators can be developed to enhance beneficial 
effects of FXR activation, while minimizing off-target effects. 
 
1.2: The Role of Epigenetic Mechanisms in Regulatin g Nuclear Receptor 
Function: 
Conrad Waddington first introduced the term ‘epigenetics’ in 1942 to describe the 
interaction of genes with the environment which brought about a certain phenotype.  
Epigenomics was later coined as the study of chromatin structure, packaging of DNA 
around nucleosomes, covalent modifications of histone tails, DNA methylation (Murrell 
et al., 2005), non-coding RNAs, particularly microRNAs (Jirtle and Skinner, 2007), as 
well as other mechanisms. These epigenetic mechanisms are thought to be involved in 
processes such as development, tissue-specific expression of genes, senescence, 
development of diseases, such as cancer, as well as many other processes. All of these 
epigenetic mechanisms function to alter the expression of genes without altering the 
underlying genetic information. 
  In order for nuclear receptors to bind to response elements in DNA and initiate 
transcription of target genes a permissible chromatin environment is essential to expose 
DNA response elements. Chromatin rearrangement can typically occur through 
modifications to histones comprising nucleosome cores that allow localized chromatin to 
transition from a close conformation to an open conformation. In the context of nuclear 
receptor mediated transcriptional activation, chromatin modification occurs through the 
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recruitment of coactivators to target gene binding sites. Therefore, in order for nuclear 
receptors to induce transcription of target genes, an intricate organization of cofactor 
recruitment and chromatin modification is necessary. 
Emerging results have shown that the recruitment of nuclear receptors and 
cofactors to target gene regulatory regions occurs in a specific sequential order 
(Metivier et al., 2006). In fact, it has been suggested that in order for a nuclear receptor 
to bind to its response element in a target gene regulatory region binding of another 
factor is necessary to direct nuclear receptor binding, which referred to as a pioneer 
factor. Therefore, expression of a nuclear receptor in a cell type or tissue alone is not 
sufficient to induce transcription of target genes. The remainder of this section will 
discuss common histone modifications associated with active and repressed gene 
transcription and an overview of cofactors and pioneer factors that are involved in 
nuclear receptor-mediated transcriptional regulation. 
 
1.2.1: Overview of histone modifications associated  with active/repressed gene 
transcription. 
Nucleosomes make up the basic unit of chromatin. Nucleosomes are comprised 
of 146 base pair strings of DNA wrapped around core histone proteins, H2A, H2B, H3 
and H4, linked by a 200 base pair string of DNA between each unit (Kouzarides, 2007; 
Luger et al., 1997; Trotter and Archer, 2008; Wolffe, 2001). The DNA that is wrapped 
around the histone complex is unavailable for the binding of a TF or for the initiation of 
transcription. In order for a TF or nuclear receptor to bind to its response elements with 
the promoter or enhancer region of a target gene and initiate transcription, the tightly 
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wound chromatin in these regions needs to be released by unwinding allowing the 
binding sites to be exposed. Furthermore, chromatin needs to be further modified and 
unwound to allow other mediators to associate with the transcription complex, such as 
RNA polymerase II (RNA Pol II), and to allow optimal space for DNA-protein interactions. 
All of these actions are suggested to occur through the epigenetic modification of 
histone tails (Kouzarides, 2007). These modified histones then alter their conformation 
in such a way that they free bound DNA in order for transcription to occur.   
 There are multiple posttranscriptional modifications that can occur to tails of 
histones 1-9 (H1-H9). Some of the more significant histone modifications are: 
methylation of arginines; methylation, acetylation, ubiquitination, ADP-ribosylation, and 
sumoylation of lysines (K); and phosphorylation of serines and threonines (Bernstein et 
al., 2007; Kouzarides, 2007). How each modification alters the histone-DNA complexes 
and what role these modifications have on transcription, DNA-replication, DNA repair or 
other mechanisms is not fully known. However, recent studies have begun to elucidate 
some of these roles (Kouzarides, 2007). For example, in the instance of transcription 
initiation instigated by binding of a TF, it has been shown that mono-, di- and tri-
methylation of histone 3 lysine 4 (H3K4) and lysine 36 (H3K36) is highly associated with 
actively transcribed genes (Bernstein et al., 2007; Heintzman et al., 2007; Li et al., 
2007). Conversely, methylation of H3 lysine 9 (H3K9), H3 lysine 27 (H3K27), and H4 
lysine 20 (H4K20) correlates with gene repression (Bernstein et al., 2007). Acetylation 
of histone lysines causes a neutralization of charge resulting in relaxation in the 
nucleosome core, and therefore is almost always associated with active transcription 
(Bernstein et al., 2007; Kouzarides, 2007). Activation of nuclear receptors leads to 
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recruitment of coactivators which are responsible for mediating these histone 
modifications. This process will be described in more detail below. 
 
1.2.2: Overview of cofactors and pioneer factors th at are involved in nuclear 
receptor-mediated transcriptional regulation.  
As mentioned, in order for nuclear receptors to bind to response elements in 
DNA and initiate transcription of target genes a permissible chromatin environment is 
needed, which is accomplished through modifications to histones comprising 
nucleosome cores allowing localized chromatin to transition to an open conformation. 
Nuclear receptors initiate chromatin modification through the recruitment of coactivators 
to target gene binding sites. These coactivators include the SRC family of proteins and  
provide a scaffold for the recruitment of other coactivators including histone 
acetyltransferases (HAT) and histone methyltransferases, which covalently modify 
histones to allow for a permissible chromatin environment necessary for induction of  
nuclear receptor mediated transcription (Berger, 2007; Kinyamu and Archer, 2004; 
Kouzarides, 2007; Perissi and Rosenfeld, 2005; Stallcup et al., 2003). In addition to this, 
ATP-dependent chromatin remodeling complexes are also recruited to target gene 
promoters in order to further modify localized chromatin to allow for other cofactors and 
transcriptional machinery to bind and initiate target gene transcription (Aoyagi and 
Archer, 2008; Aoyagi et al., 2005).  
Research is currently being conducted to analyze where nuclear receptors bind 
within target genes and how binding alters the structure of chromatin in order to illicit 
transcription. One such TF suggested to regulate this process is foxhead box protein A1 
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(FOXA1; hepatocyte nuclear factor 3β). FOXA1 is a pioneer factor involved in 
recruitment of estrogen receptor alpha (ERα) to cis-regulatory elements within target 
genes in order to induce transcription (Lupien et al., 2008). Studies have shown FOXA1 
binding highly correlates with H3K4 di-methylation to the promoter regions of actively 
transcribed FOXA1 target genes (Lupien et al., 2008). In addition, FOXA1 binding is 
absolutely essential for the proper transcriptional activation of ER target genes (Hurtado 
et al., 2011; Lupien et al., 2008). Studies describing the involvement of pioneer factors 
and epigenetic modifications, such as H3K4 di-methylation, in regulating ERα-induced 
transcription of target genes implicates that FXR also initiates transcription of its target 
genes through associations with similar epigenetic mediators. However, which cofactors 
and epigenetic mediators are involved in FXR-induced transcription of target genes 
needs to be experimentally determined.   
It has already been shown that binding of ligands to FXR induces a conformation 
change that releases interactions to the corepressors silencing mediator of retinoic acid 
and thyroid hormone receptor (SMRT) and nuclear corepressor (NCOR), and recruits 
the coactivators steroid receptor coactivator 1 (SRC-1), peroxisome-proliferator-receptor 
(PPAR)-gamma-coactivator-1α (PGC1α; Savkur et al., 2005; Zhang et al., 2004), 
coactivator associated arginine methyl transferase-1 (CARM-1; Ananthanarayanan et 
al., 2004; Bauer et al., 2002), protein arginine methyl transferase-1 (PRMT-1; Rizzo et 
al., 2005), and other coactivators (Modica et al., 2010). And therefore, FXR functions to 
initiate transcription of target genes in much the same manner as other nuclear 
receptors. However, knowledge of how FXR initiates transcription of target genes in a 
tissue-specific manner is still lacking. A few tissue-specific target genes for FXR have 
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already been determined. For example, even though FXR is highly expressed in liver 
and intestine, it only induces expression of FGF15 in intestine and BSEP in liver 
(Ananthanarayanan et al., 2001; Inagaki et al., 2005). Other tissue-specific factors and 
epigenetic mechanisms are likely responsible for regulating tissue-specific functions of 
FXR. Determining the epigenetic mechanisms involved in FXR-induced transcription of 
FXR target genes can greatly enhance our understanding of the cellular machinery 
involved in FXR target gene expression. 
 
1.3: Introduction to HNF4 α in regulating liver homeostasis: 
Hepatocyte nuclear factor 4 alpha (HNF4α) is encoded by the gene HNF4A and 
has been shown to be a critical factor for regulating both embryonic and adult liver 
development (Hayhurst et al., 2001; Watt et al., 2003). HNF4α is an essential regulator 
of the transcription of genes involved in hepatocyte cell lineage important for liver 
development (Strick-Marchand and Weiss, 2002). HN4α localizes mainly to the nucleus, 
binds DNA exclusively as a homodimer, and recognizes response elements consisting 
of direct repeats, namely direct repeats separated by one nucleotide (DR-1; Bogan et al., 
2000; Jiang et al., 1995; Jiang and Sladek, 1997). HNF4α regulates the transcription of 
several liver specific genes including genes involved in the production of clotting factors, 
apolipoprotein synthesis, and drug metabolism (Gonzalez, 2008; Watt et al., 2003). In 
addition, HNF4α has been shown to directly regulate the transcription of CYP7A1, the 
rate-limiting enzyme in bile acid synthesis, suggesting HNF4α also has a role in 
regulating bile acid homeostasis (Inoue et al., 2004). Studies have shown that HNF4α is 
capable of enhancing the liver-specific functions of other type II nuclear receptors. For 
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example, HNF4α has been shown to cooperatively enhance the transcriptional activity 
of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) at the 
cytochrome p450 3A4 (CYP3A4) promoter (Tirona et al., 2003). Whether HNF4α 
functions to regulate FXR activity has not been determined. However, evidence exists 
showing correlative roles of these two factors in bile acid homeostasis and suggests 
that HNF4α could be an important factor involved in the regulation of tissue-specific 
functions of FXR. 
 
1.4: Introduction to role of FXR in colon cancer pr ogression: 
Colon cancer is a leading cause of cancer related deaths in the United States. 
Although inheritable genetic factors contribute significantly, diets high in saturated fat 
and low in fiber comprise a major risk factor for colon cancer development (Armstrong 
and Doll, 1975). Dietary fats are emulsified by primary bile acids in the proximal 
intestines in order for proper digestion and absorption and high-fat diets can lead to an 
elevated intestinal bile acid load. Furthermore, low dietary fiber can increase the 
gastrointestinal transit time, and together, these factors can increase both the level and 
time of bile acid exposure (Correa, 1981; Willett et al., 1990).   
In the distal ileum and colon, primary bile acids are converted to secondary bile 
acids by intestinal microflora.  Secondary bile acids, DCA and LCA, are considered to 
be more cytotoxic compared to primary bile acids, CA and CDCA, due to their 
detergent-like properties and higher hydrophobicity (Hofmann, 1999). DCA and LCA 
have been shown to induce colonic epithelium cytotoxicity through oxidative stress and 
promote cell proliferation, and therefore, have been linked to increased colon 
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carcinogenesis (Lechner et al., 2002). In fact, it has been shown that patients with 
colorectal cancer have elevated levels of secondary bile acids in their feces (Bianchini 
et al., 1989; Hill et al., 1975; Reddy et al., 1978).  
As mentioned earlier, FXR functions to regulate the synthesis, transport, 
intestinal re-absorption, and free intracellular concentration of bile acids (Figure 3 ). This 
process is essential for preventing the accumulation of bile acids to cytotoxic levels 
(Inagaki et al., 2005; Okuwaki et al., 2007; Sinal et al., 2000; Tu et al., 2000; Zollner et 
al., 2006). Independently of bile acids, FXR has also been shown to attenuate the 
development of intestinal tumors in mouse models of colon cancer (Maran et al., 2009; 
Modica et al., 2008). This suggests that FXR may serve as a tumor suppressor for the 
development of colon cancer. However, the exact mechanisms involved in FXR-induced 
tumor suppression are unknown. One mechanism could be through the protection of 
colonic epithelium from bile-acid toxicity by inducing intracellular trafficking proteins and 
efflux transporters while suppressing the expression of bile acid influx transporters and 
the de novo synthesis of bile acids. However, FXR appears to have anti-tumorigenic 
functions independent of its regulation of bile acid homeostasis. For example, FXR 
deficiency has been suggested to increase susceptibility to colon cancer development 
by increasing epithelial permeability to bacteria and promoting WNT/β-catenin signaling 
as a result of tumor necrosis factor alpha (TNFα) released from infiltrating macrophages 
(Inagaki et al., 2006; Modica et al., 2008). Likewise, FXR deficiency has also been 
shown to promote the development of hepatocellular carcinoma (HCC) through 
stimulation of WNT and nuclear factor kappa B (NFκB) signaling (Kim et al., 2007; 
Wang et al., 2008; Wolfe et al., 2011; Yang et al., 2007). Furthermore, constitutive 
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activation of FXR in colon cancer cell lines protects cells against tumorigenesis, via 
suppression of cellular proliferation and activation of apoptosis (Modica et al., 2008). 
Therefore, a bile acid-independent anti-tumorigenic role of FXR is highly likely. 
FXR expression is inversely related to the malignancy of colon cancer cell lines  
suggesting that colon cancer cells have developed a mechanism to selectively decrease 
FXR expression (De Gottardi et al., 2004). Although polymorphisms present in the FXR 
gene have been identified and associated with decreased function in intrahepatic 
cholestasis of pregnancy (ICP; Marzolini et al., 2007), to date, no clinically known 
mutations exist within the FXR gene to explain the decrease in FXR expression or 
function in human colon cancer. Therefore, it has been proposed that FXR expression 
may be regulated by epigenetic mechanisms. DNA methylation is a common cellular 
mechanism responsible for suppressing gene expression during development or 
tumorigenesis. The purpose of this project was to elucidate whether DNA methylation of 
the FXR gene is responsible for FXR reduction in human colon cancer. 
 
1.5: Introduction to DNA Methylation in Cancer: 
Tumor suppressor genes are commonly down-regulated in cancer cells by DNA 
methylation of their promoters (Baylin et al., 1998). However, covalent DNA methylation 
can occur within promoter regions, introns, and/or 3’ UTRs of a tumor suppressor gene.  
Methylation typically occurs within regions of the gene that are rich in CpG sites, or 
otherwise known as CpG islands (Jones and Baylin, 2002; Takai and Jones, 2002). A 
CpG island is defined as sequences greater than 200 bp in length, with GC content 
greater than 50% and an observed CpG/expect CpG ratio of 0.6 or greater (Takai and 
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Jones, 2002). Four active DNA methyltransferases (DNMT) have been identified in 
mammals, DNMT1, DNMT2, DNMT3A and DNMT3B. However, only DNMT1 and 
DNMT3B are mainly responsible for aberrant DNA methylation (Jones and Baylin, 2002; 
Rhee et al., 2002). Which one(s) of these, if any, is specifically involved in the 
methylation of the FXR gene is not known.   
 
1.6: Concluding Introductory Remarks: 
Over the last few decades, there has been an extensive amount of research 
done to elucidate the physiological roles of FXR. In 20 years, identification of FXR 
functions has gone from being an unknown orphan nuclear receptor capable of 
heterodimerizing with RXRα in yeast to being a critically important mediator of bile acid 
homeostasis, lipid and glucose metabolism, and protecting the integrity of the liver and 
intestine. This research has determined FXR as a very promising therapeutic option for 
multiple metabolic diseases, which is quite intriguing given the major health impact 
these diseases have on the United States, as well as the rest of the world. However, 
because FXR remains a relatively “new” member of the nuclear receptor superfamily, 
much is still left to understand about FXR functions, including the epigenetic 
mechanisms involved in FXR-induced transcription and cell-specific expression of FXR.  
New technological advances have made it possible to further understand 
epigenetic mechanisms involved in nuclear receptor activity on a genome-wide scale. 
Elucidating how FXR functions on a genome-wide scale and the epigenetic 
mechanisms involved in regulating FXR function, will have a profound effect on 
developing pharmacological FXR modulators and on the field of nuclear receptor 
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research. In addition, understanding epigenetic mechanisms involved in regulating cell-
specific expression of FXR, namely expression in hepatocytes and enterocytes, will help 
elucidate the role FXR plays in diseases, such as liver and colon cancer, and determine 
whether FXR is a potential therapeutic option for these diseases. The ultimate goal of 
this thesis is to further elucidate the epigenetic mechanisms involved in mediating FXR 




Chapter 2: Statement of Purpose 
 
2.1: Significance: 
FXR has become a potential therapeutic target for the treatment, prevention, 
and/or diagnosis of several diseases, including cholestasis, fatty liver disease, 
hyperlipidemia, and liver and colon cancer. However, knowledge of the epigenetic 
mechanisms involved in FXR-mediate transcriptional regulation of target genes and in 
FXR silencing in colon cancer is lacking. Understanding these processes is absolutely 
essential for the development of FXR modulators as well as for understanding FXR’s 
role in the etiology of these diseases. My dissertation was, therefore, designed to 
elucidate the epigenetic mechanisms involved in: 1) regulating genome-wide FXR 
binding in liver and intestine; and 2) regulating FXR expression in human colon cancer.  
 
2.1.1: A comprehensive genome-wide view of FXR func tion is essential for 
understanding tissue-specific functions of FXR and for development of 
therapeutic modulators of FXR. 
The best characterized role of FXR is regulating the enterohepatic circulation of 
bile acids. However, research over the past decade has revealed FXR also critically 
regulates lipid and glucose metabolism, and serves a tumor suppressive role for liver 
and colon cancer development. In addition to this, tissue-specific gene regulation of 
FXR has already been determined for some genes.  For example, FXR has been 
determined to regulate the expression of FGF15 and ASBT in intestines but not liver 
(Inagaki et al., 2005; Li et al., 2005). Conversely, FXR has been shown to regulate 
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BSEP and NTCP in liver but not intestines (Ananthanarayanan et al., 2001; Plass et al., 
2002; Zollner et al., 2005). However, the degree of FXR tissue-specificity on a genome-
wide scale and the epigenetic mechanisms involved remain unknown.  
Until the recent development of genome-wide binding technology, obtaining 
information on the direct effects of TF binding on target gene expression has been 
difficult. Previously, this information was obtained by microarray analysis. However, 
because FXR can regulate gene transcription via several methods, using microarray 
analysis for understanding the global effects of FXR activation on target gene 
expression has its limitations. For example, FXR can regulate expression of genes by 
directly binding to regulatory regions within DNA and either initiate or repress 
expression of the gene. This is in fact how FXR regulates the transcription of target 
genes SHP, APOC-III, and apolipoprotein A-I (APOA-I; Claudel et al., 2003; Claudel et 
al., 2002; Lu et al., 2000). However, FXR can also regulate gene transcription indirectly 
through up-regulating the transcription of other transcription modulators. For example, 
SHP is considered a universal inhibitory protein. Up-regulation of SHP by FXR results in 
the inhibition of transcription of other genes such as LRH-1, CYP7A1 and SREBP-1c 
(Lu et al., 2000; Watanabe et al., 2004). Finally, FXR can regulate the transcription of 
genes through regulation of bile acid levels. Bile acids themselves can serve as 
signaling molecules. For example, bile acids can bind to an activate a G-protein couple 
receptor, TGR5, resulting in increased intracellular cAMP levels, activation of MAP 
kinase signaling cascades, and induction of gene transcription, independent of its 
effects on FXR activity (Kawamata et al., 2003; Maruyama et al., 2002; Takeda et al., 
2002). In order to fully elucidate the direct effects of FXR activity on gene expression, a 
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genome-wide binding analysis is necessary. In addition, genome-wide binding analysis 
will help elucidate the extent of FXR’s role in other cellular processes, such as lipid 
metabolism, glucose metabolism, and tumor suppression, on a genome-wide scale. 
This project was designed to investigate the genome-wide binding of FXR in liver 
and intestine in order to get a better understanding of genome-wide tissue-specific 
functions of FXR. This analysis should yield interesting information on the degree of 
tissue-specific binding of FXR in liver and intestine, molecular pathways regulated by 
FXR in liver and intestine, and will suggest some novel ideas of how FXR regulates 
transcription of target genes. In addition, genome-wide binding analysis of FXR will help 
determine the degree of binding of FXR to desirable and non-desirable target genes, 
which is critical for the development of FXR modulators. 
 
2.1.2: Orphan nuclear receptors, namely HNF4 α, and epigenetic mediators may 
help to regulate FXR function. 
Information gained from genome-wide binding of FXR in liver and intestine 
revealed evidence of orphan nuclear receptors regulating FXR function. Much has 
already been discussed regarding the recruitment of chromatin modifying enzymes and 
cofactors involved in FXR induced transcription of target genes. However, little is known 
about the interaction of FXR with other orphan nuclear receptors. The significance of 
this is profound because of the implications on pharmacologically targeting an orphan 
nuclear receptor to modulate specific functions of FXR. This could be a potential 
therapeutic option for targeting desirable FXR activity while minimizing off-target effects. 
In addition, elucidating the coordination of FXR activity with other orphan nuclear 
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receptors adds to the overall scientific understanding of FXR function and further 
progresses the nuclear receptor field.  
HNF4α is an orphan nuclear receptor that transcriptionally regulates several 
liver-specific genes. In addition, HNF4α has been shown to regulate both the synthesis 
and metabolism of bile acids suggesting it has overlapping function with FXR (Inoue et 
al., 2004). Furthermore, HNF4α has been shown to cooperatively enhance the 
transcriptional activity of other type II nuclear receptors in the liver, CAR and PXR 
(Tirona et al., 2003), and therefore, may likely facilitate liver-specific functions of FXR. 
Consequently, a comprehensive study on the role of HNF4α in regulating liver-specific 
functions of FXR on a genome-wide scale is necessary. 
 
2.1.3: Understanding the role of FXR and the mechan ism of FXR down-regulation 
in colon cancer could provide valuable information for targeting FXR for the 
prevention, treatment, and/or diagnosis of colon ca ncer. 
Previous studies have shown that FXR expression is decreased in human colon 
cancer (De Gottardi et al., 2004). In addition, mice deficient in FXR have increased 
colon tumorigenesis, increased intestinal permeability and WNT/β-catenin signaling, 
increased NFκb signaling, suggesting FXR as a tumor suppressor (Inagaki et al., 2006; 
Maran et al., 2009; Modica et al., 2008; Wang et al., 2008; Wolfe et al., 2011). It is 
suggested that the tumor suppressive role of FXR is two-fold. One, FXR regulates the 
synthesis and transport of bile acids preventing the accumulation of free bile acids and 
attenuating the tumorigenic effects of bile acids. And two, FXR suppresses colonic 
tumorigenesis independent of its regulation of bile acid levels, and directly regulates 
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transcription of anti-tumorigenic genes. Nevertheless, the suppression of FXR in 
intestinal epithelial cells clearly increases intestinal susceptibility to tumorigenesis. 
Therefore, reversing FXR silencing could be one mechanism exploited to slow the 
progression of colon cancer. The purpose of this study was to identify the molecular 
mechanisms involved in silencing FXR gene expression in human colon cancer so that 
it can be further determined whether FXR serves as a potential target for the treatment, 
prevention, and/or diagnosis of human colon cancer. 
 
2.2: Overall Hypothesis:  
Epigenetic mechanisms function to modify the transcription of genes without 
changing the underlying genomic sequence. Over the past decade, much research has 
been done elucidating chromatin modifications and cofactors involved in nuclear 
receptor induced transcription. However, due to recent technological advancements, 
this analysis has been extended to a more genome-wide scale. A primary focus is to 
further understand the epigenetic mechanisms involved in FXR-induced transcriptional 
regulation on a genome-wide scale and FXR silencing in human colon cancer. The 
central hypothesis is that epigenetic mechanisms, specifically interactions with orphan 
nuclear receptors, function to regulate binding of FXR in liver and intestine and that 
DNA methylation is the epigenetic mechanism responsible for FXR silencing in human 
colon cancer. These hypotheses will be tested via three Specific Aims. Following the 
completion of this study, a better understanding of FXR’s tissue-specific functions on a 
genome-wide scale and of the molecular mechanisms involved in FXR silencing in 




2.3: Specific Aims: 
2.3.1: Specific Aim 1: Identify direct genome-wide FXR binding sites in liver and 
intestine. 
In order to elucidate the epigenetic mechanisms involved in regulating genome-
wide functions of FXR, a comprehensive understanding of direct FXR binding sites in 
liver and intestine, two main tissues for FXR function, is needed. In this aim, the 
following objectives were determined. 
 2.3.1a. Compare the degree of tissue-specific binding of FXR in mouse liver and 
intestine. 
 2.3.1b. Determine genome-wide binding distribution of FXR in liver and intestine. 
2.3.1c. Motif analysis of FXR binding sites in liver and intestine. 
 2.3.1d. Pathway analysis of FXR binding in liver and intestine. 
 2.3.1e. Identification of novel FXR binding patterns to known and unknown target 
genes. 
 
2.3.2: Specific Aim 2: HNF4 α functions to co-regulate FXR function in the liver . 
Genome-wide binding analysis of FXR in liver and intestine suggested the 
involvement of orphan nuclear receptors in regulating FXR function. HNF4α is a newly 
adopted orphan nuclear receptor shown to highly regulate many liver-specific functions. 
Therefore, the role of HNF4α in regulating FXR function on a genome-wide scale was 
investigated. In this aim, the following objectives were determined. 
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 2.3.2a. Compare genome-wide binding of FXR and HNF4α in liver to assess the 
degree of overlapping binding. 
 2.3.2b. Determine distance of FXR and HNF4α binding from each other at 
shared target sites. 
 2.3.2c. Confirm binding of FXR and HNF4α to shared target genes and assess 
the dependence of binding of each factor on the presence of the other factor by 
chromatin immunoprecipitation (ChIP) followed by quantitative PCR (ChIP-qPCR) using 
FXR knockout mice. 
2.3.2d. Determine whether FXR and HNF4α physically interact using co-
immunoprecipitation (co-IP) assays. 
 2.3.2e. Determine the effect of HNF4α on regulating FXR-induced transcriptional 
activity of shared target sites. 
 
2.3.3: Specific Aim 3: FXR is down-regulated in human colo n cancer by DNA 
methylation of the FXR promoter. 
As described, FXR is highly down-regulated in human colon cancer and mouse 
models of intestinal cancer. This aim was designed to elucidate the molecular 
mechanisms involved in silencing FXR in human colon cancer. In this aim, the following 
objectives were determined. 
 2.3.3a. Confirm degree of FXR and FXR target gene down-regulation in a mouse 
intestinal cancer model, APCmin mice, and in human colon cancer samples. 
 2.3.3b. Assess the effects of DNMT inhibition on FXR expression in human colon 
cancer cell lines. 
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 2.3.3c. Identify any CpG islands located within the FXR promoter by methylated 
DNA immunoprecipitation (MeDIP) analysis. 
 2.3.3d. Correlate degree of FXR promoter methylation with FXR expression in 
human colon cancer cell lines by bisulfite sequencing. 
 2.3.3e. Assess the effects of siRNA knockdown of DNMTs on FXR expression in 









3.1: Animals and Treatment: 
All animals were housed in the AAALAC-accredited facilities at the University of 
Kansas Medical Center under a standard 12-hr light/12-hr dark cycle with access to 
chow and water ad libitum. All protocols and procedures were approved by the IACUC 
committee at the University of Kansas Medical Center. 
 
3.1.1: Animals used for genome-wide binding studies  and ChIP-qPCR. 
Ten week-old wild-type (WT) or whole body FXR KO male mice (n=4 to 5 per 
group), in C57BL/6 genetic background, were fasted overnight and then gavaged with 
vehicle (1% methylcellulose, 1% Triton X-100 in PBS) or GW4064 (75 mg/kg). GW4064 
was synthesized by the Chemical Discovery Laboratory at the University of Kansas, 
Lawrence, KS. Liver and intestines (ileum and colon) were collected 2, 4, or 8 hrs later.  
For ChIP-qPCR analysis, optimal GW 4064 treatment groups for liver and 
intestine were determined to be 4 and 2 hr treatment times, respectively. Therefore, 
these tissues were used for FXR and/or HNF4α ChIP-qPCR analysis. 
 
3.1.2: Animals for co-IP assays. 
For co-IP assays, 4 month-old WT and FXR KO mice (n=3 per group), in 
C57BL/6 genetic background, were fed control diet or a diet supplemented with 1% 
(w:w) cholic acid (CA). Liver tissues were isolated after 5 days of treatment and whole 
cell lysates were prepared for immunoprecipitation assays. 
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3.1.3: Animals for FXR expression. 
WT and APCmin mice in C57BL/6 genetic background were obtained from 
Jackson Laboratories (Bar Harbor, Maine). One-year old male and female APCmin mice 
(n=4 per group) were used to evaluate the expression of FXR. APCmin mice carry a 
nonsense mutation in the APC (adenomatous polyposis coli) gene, are a well known 
intestinal carcinogenesis mouse model, and develop tumors in the small intestine (Su et 
al., 1992).  
 
3.2: ChIP-sequencing: 
3.2.1: Chromatin immunoprecipitation for sequencing .  
This procedure was performed by Genpathway, Inc (San Diego, CA). Briefly, 
flash frozen tissues were fixed in formaldehyde before quenching with glycine. The 
nuclei were extracted and sonicated to yield 500-1000 bp DNA fragments. Chromatin 
was pre-cleared with blocked Staph A cells (Pansorbin, CalBiochem, San Diego, CA) 
before incubation with a ChIP-quality anti-FXR antibody (H-130x, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA). Antibody specificity for mouse FXR was validated 
and is presented in Figures 5a and 5b. Samples were incubated with prepared Staph A 
cells to extract antibody-chromatin complexes, followed by washing and elution. DNA 
fragments associated with the FXR antibody were released and purified. The purified 
DNA fragments were first analyzed by quantitative PCR (qPCR) with primers amplifying 









Figure 5: FXR antibody specificity. a) Western blot analysis of nuclear extracts from 
WT (lane 1) and FXR KO (lane 2) mouse liver using antibodies against FXR or loading 
control protein, PARP. b) ChIP-qPCR analysis of WT and FXR KO mouse livers. Fixed, 
sonicated chromatin prepared from WT and FXR KO mouse livers was 
immunoprecipitated using antibody against FXR. The IP DNA was then PCR amplified 






For HNF4α ChIP-Seq, ChIP experiments were done as previously reported 
(Schmidt et al., 2010). Raw data were obtained from ARRAYEXPRESS Archive 
(European Bioinformatics Institute; E-TABM-722; Schmidt et al., 2010). 
 
3.2.2: Sequencing analysis of ChIP DNA.  
ChIP DNA fragments associated with the FXR antibody were amplified using the 
Illumina ChIP-Seq DNA Sample Prep Kit (San Diego, CA). The DNA libraries generated 
were further tested by qPCR at the same specific genomic regions as the original ChIP 
DNA to assess quality of the amplification reactions. DNA libraries were sequenced on 
a Genome Analyzer II by Illumina Sequencing Services. After sequencing, data files 
were processed through Genome Analyzer Pipeline Software (Illumina) and mapped to 
the genome. Enriched intervals, referred to as peak values, were defined when a given 
region appeared more than 20 times (a conservative threshold was arbitrarily set at > 
20). A genomic region containing more than one enriched interval overlapping by at 
least one base pair was defined as an active region. The wiggle (WIG) formatted files 
are stored in the UCSC database 
(http://genome.ucsc.edu/goldenPath/customTracks/custTracks.html#Mouse) and can be 
downloaded using UCSC Genome Browser (Kent et al., 2002). 
The distribution of FXR binding sites relative to target gene TSS was analyzed by 
JMP 7.0.  Analysis was done to determine the average peak value of FXR binding as 
well as to determine the total number of FXR binding events in relation to distance of 
site from a gene TSS.   
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Histograms of FXR and/or HNF4α binding to target genes were generated using 
Affymetrix Integrated Genome Browser (IGB) or UCSC Genome Browser (Kent et al., 
2002; Nicol et al., 2009).  
 
3.2.3: ChIP-Seq analysis of FXR and HNF4 α in mouse livers. 
ChIP-seq for FXR was performed on mouse livers as described above, and for 
HNF4α as previously described (Schmidt et al., 2010). Raw FXR and HNF4α ChIP-
sequencing data were generated from single end sequencing on an Illumina Genome 
Analyzer and were re-analyzed using Model-based Analysis of ChIP-Seq (MACS). It is 
important to note that ChIP-seq analysis was done in livers from different mice. Total 
FXR binding sites in liver were compared to total HNF4α binding sites in liver. The 
binding frequency of HNF4α relative to FXR binding site was analyzed using BEDtools 
(Quinlan and Hall, 2010). 
 
3.2.4: Motif identification.  
ChIP-seq peaks unique to liver, intestine or both were used to define tissue-
specific FXR-DNA binding motifs. Using the midpoint from the 500 highest peak values 
for each tissue as a reference, 48 bp sequences flanking either side were retrieved from 
the UCSC Browser (Kent et al., 2002). Each file was then independently run using 
MEME (Multiple Em for Motif Elicitation; Bailey and Elkan, 1994). MEME uses a 
position-dependent letter probability matrix that describes the probability of each 
possible letter at each position in the pattern. Individual MEME motifs do not contain 
gaps. Patterns with variable-length gaps were split by MEME into two or more separate 
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motifs. Motifs containing or resembling the canonical ‘AGGTCA’ motif (which were also 
the highest scoring motifs) were cross compared between tissues. 
 
3.2.5: Pathway analysis.  
Peaks identified in ChIP-seq data, in both liver and intestine, that were located 0-
2 kb upstream from TSSs were analyzed using the Functional Annotation Tool in DAVID 
(DAVID; http://www.david.niaid.nih.gov; Dennis et al., 2003). For a pathway or process 
to be defined, the threshold count was set at 2 with a minimum EASE (Expression 
Analysis Systematic Explorer) score, a modified Fisher Exact Test, of 0.1. Only 
Bonferroni corrected p-values with false discovery rates (FDRs) less than or equal to 
0.1 were accepted. 
 Pathway analysis of direct target genes shared by FXR and HNF4α in mouse 
liver was also analyzed by DAVID as described above. Processes for this analysis with 
a p-value less than or equal to 0.05 were accepted. 
. 
3.3: ChIP-qPCR Assays. 
ChIP assays were performed on livers and intestines of mice treated with 
GW4064 or vehicle once for 4 and 2 hrs, respectively. Briefly, flash-frozen livers were 
minced and fixed in 1% formaldehyde for 15 min and then quenched with 0.125 M 
glycine. Nuclear extracts were prepared and sonicated to yield 500-1000 bp DNA 
fragments. Sonicated chromatin was aliquoted to yield 20 mg tissue equivalents for 
each immunoprecipitation assay.   
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For FXR ChIP-qPCR, samples were pre-cleared with protein agarose G-salmon 
sperm DNA beads (Millipore Corp, Billerica, MA) before incubation with an IgG antibody 
or the anti-FXR antibody (H-130x, Santa Cruz Biotechnology, Inc). Samples were 
incubated with prepared protein agarose G-salmon sperm DNA beads in order to 
extract antibody-chromatin complexes. Complexes were washed and eluted with 
immunoprecipitation elution buffer. DNA fragments associated with the FXR antibody 
were released by incubating samples in a 450 mM NaCl solution at 65oC for 5 hrs. RNA 
and protein were degraded by treating chromatin with RNase A and proteinase K. DNA 
fragments were purified by standard DNA column purification. The purified DNA 
fragments that were bound by FXR were analyzed by qPCR using primers that amplify 
FXR binding sites (Table 1a-1b ). QPCR reactions were carried out using MaximaTM 
SYBR Green (Fermentas; Glen Burnie, MD). Data was analyzed as fold change over 
IgG negative controls.  
For HNF4α ChIP-qPCR analysis, assays were done as described above. Livers 
of WT and FXR KO mice treated for 4 hrs with vehicle or GW4064 were used for 
analysis. Immunoprecipitation was done using anti-HNF4α antibody (PP-H1415-00, 
R&D Biosystems, Minneapolis, MN) and Dynabeads Protein G (Invitrogen, Carlsbad, 
CA). The purified DNA fragments were analyzed by qPCR with primers amplifying 
shared FXR and HN4α binding sites (Table 1a and 1c). 
 
3.4: Co-IP: 
Co-IP assays were done on whole cell liver extracts from WT mice fed diet with 
or without 1% CA and FXR KO mice fed control diet. The assay was done using a co-IP 
kit from Invitrogen. Specifically, whole cell lysates from mouse livers were prepared  
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Table 1a: Primers for ChIP-qPCR assays. 
 
Primer Name Primer Sequence: 5'-3' 
Nr0b2 -320 to -220  For (for initial q-PCR)  CTGGTTGAGCGCCTGAGAC 
Nr0b2 -320 to -220 Rev (for initial q-PCR)  CTGCCTGGATGCCCTTTATC 
Ostb -220 to -150 For (for initial q-PCR)  CCGCAATGGCAGATCATAC 
Ostb -220 to -150 Rev (for initial q-PCR)  GTGAATGACCCCACGAATG 
Osta -1245 to -1145 For (for initial q-PCR)  CAGTGGAAGTGGCTTGAGTC 
Osta -1245 to -1145 Rev (for initial q-PCR)  GGGCAGGAGAGGAAGCTAAG 
Untr6 For TCAGGCATGAACCACCATAC 
Untr6 Rev AACATCCACACGTCCAGTGA 
Shp -320 to -220 For GCCTGAGACCTTGGTGCCCTG                    
Shp -320 to -220 Rev CTGCCCACTGCCTGGATGC                       
Shp +950 to +1050  For CAGTCCACGCCCTCAGCCC                   
Shp +950 to +1050  Rev GGCAGGAGGAGGTCTGAAAGC                  
Ostb -220 to -150 For  TGGGCTCCTGGCACTTTCGG                      
Ostb -220 to -150 Rev TGGGACTTCAGGCTGGGTGG                      
Osta -1245 to -1145 For CAGCTCCCTCTTGCCCTCC                         
Osta -1245 to -1145 Rev TAGACAGTTCACCATGTCTCTTGAGTCC 
Bsep -100 to -10 For CCTCTCACCAGGCTCTCTACC                    
Bsep -100 to -10 Rev CGCCACTGTGGAAAGTCAGGG                   
Fgf15 1900 to 2000  For CCTGCCTGGTGGCTCTGTCTC                     
Fgf15  1900 to 2000 Rev GGATAATCCGCAACTCCTCCCGCC           
Slc9a8 (Nhe8) -5350 to -5250 For AGAAGAGCCTAGGACTTTCCCACA 
Slc9a8 (Nhe8) -5350 to -5250 Rev TCTGGCTGGTCACACTGGTTAAGA 
Slc25a3 -7770 to -7670 For ATTGGGTGTAGCTTGAGTGGAGGA 
Slc25a3 -7770 to -7670 Rev TGACCCATAAAGGGTGTGGTGGTT 
Hmga1 -3650 to -3550 For TGGTTTGGGCTAGGTCAGGTTGAT 
Hmga1 -3650 to -3550 Rev CCCAAATGTGAATGTCCCGCAGTT 
Pddc1 -470 to -370 For TCTGGATCTTCACAAACCGGCAGA 
Pddc1 -470 to -370 Rev TCCCTGAGTGGTCGTTTCCTGATT 
Fcna -950 to -850 For CTGGAGGGACAGAGGGAGGTCAGT 
Fcna -950 to -850 Rev GGCCAGACTAGGCCAGCTAT 
Fcna -4570 to -4470 For TTGTCCAGCCCAAGGACATCAAGA 
Fcna -4570 to -4470 Rev TTACAACGATGCCTTCACCCTCAC 
Sumo3 -7370 to -7270 For TGCCTTTCCTTCAGTAAGCAGCCA 
Sumo3 -7370 to -7270 Rev AAACCAGGAAGGCTGTGAGGACA 
Acads 18560 to 18660 For AGCTCTCTGGACACAACAGACACA 
Caprin1 270 to 370 For CGGTCACTCCAAGTGCCCTTCT 
Caprin1 270 to 370 Rev CAAGTGGCACCCGTTGCCTT 





Table 1b: Primers for ChIP-qPCR assays. 
 
Primer Name Primer Sequence: 5'-3' 
Actg1 -5260 to -5160 Rev GGAGCAGGAGAACGCTGGG 
Vkorc1 870 to 970 For TGAGCCATCTCACCAACTCCTGAA 
Vkorc1  870 to 970 Rev ACCTGGTGGAAGTGAAAGAAGCAG 
Tcfap2e 3080 to 3180 For GACCCAGTCGAAGGGAAAGTTG 
Tcfap2e 3080 to 3180 Rev TCTGCCTTGGGATACTGGAGTG 
Cks2 -100 to -10 For TACTCCCGCCCTCGCAATCTTG 
Cks2 -100 to -10 Rev CCAACGACCGCAGGCCCAAC 
Rorc (Rorg) 10650 to 10750 For AGAGACAGCTCCCCAATTAAGAGTG 
Rorc (Rorg) 10650 to 10750 Rev GTCTTGGATGTCCCGCTGTTGTG 
Slc10a1 (Ntcp) -8100 to -8000 For GCTGTGTTTACCCTCTGCCATC 
Slc10a1 (Ntcp) -8100 to -8000 Rev CCCTAACGTGCCTTGACCC 
Fga -5680 to -5580 For TGGGTCACAGTTGTGTCTCTCATAGC 
Fga -5680 to -5580 Rev GTGGAATCTGCCCTGCCATGTTTA 
Fga -190 to -290 For GATGTTGCCTTTGCCCTGGTCTTT 
Fga -190 to -290 Rev CTGTGTGTGGGATTCAGAGTTCATC 
Mir499 -2400 to -2300 For CTCTCCTGCACTTTGGCAACATGA 
Mir499 -2400 to -2300 Rev AAGTTTCCAGGGTAAAGGCCAGGT 
Mir126 +8650 to +8750 For GGCTGCACAAATTCAGGTCAGCAA 
Mir126 +8650 to +8750 Rev AGGATGGACTACTGGAACCCAACA 
Mir126 +9450 to +9550 For ATACCTGCCCAAGGCAGTTGAGAA 
Mir126 +9450 to +9550 Rev CACCCATCAAACTCAAGGCCAGAA 
Bccip -380 to -280 For ACAACCTGCACGCCGAGATAA 
Bccip -380 to -280 Rev TCTGTGTGTAGTGGTTTGGCCCAT 
Nat2 -580 to -480 For TACTCAACAGTGTGGTGCCAGC 
Nat2 -580 to -480 Rev CATGATATCAGGGTCCATGGGTCA 
Rarres2 -150 to -100 For TGGTGCTCCAGGCCCTCC 
Rarres2 -150 to -100 Rev CCCTCTCACCCTCTCATCTCCC 
Il17b -8280 to -8180 For CCATGTATAACACAAGTCAAGCTGTCTCC 
Il17b -8280 to -8180 Rev CTTCCCTAGTCTTTGCCCTGGTTT 
Smurf1 18350 to 18450 For TGCCCACTGCCCACATAAGTTAGA 
Smurf1 18350 to 18450 Rev ACTGCTCATTGGCTCCCTACAACA 
Gpbp1 -210 to -110 For TACTTGGGCCAGAAGGTTCTGTGGT 
Gpbp1 -210 to -110 Rev AGGTTGAGAAGTAAGAGGAGGGAG 
Pcx -60 to +40 For GCAGTCTAGTGCTGGAGAACTTTG 
Pcx -60 to +40 Rev ATTACCTTGTACCAGCCAAGCACC 
Cnnm3 -320 to -220 For CGCAAGCGCAAACCCACATACAAA 
Apoc3 -50 to 50 For TCAGGCTCTGGTCTGGACTGCTCA 
Apoc3 -50 to 50 Rev TTATATTGGCTCCAGGATGGGACAGC 




Table 1c: Primers for ChIP-qPCR assays. 
 
Primer Name Primer Sequence: 5'-3' 
Baat -150 to -50 Rev AGTAGGCTGAACCCAGAGAAGAGA 
Apoe -2100 to -2000 For TGAGGTGGTAGCTTGTGCTGACTT 
Apoe -2100 to -2000 Rev TGCTGAACTTCCAGGAACTCCGTT 
Sqsm1 13000 to 13100 For CACTGCACATGTGTGTTTCTGTGT 




according to protocol, and then immunoprecipitated using magnetic beads covalently 
linked with an antibody against FXR (H-130x, Santa Cruz Biotechnology, Inc). 
Immunoprecipitates were then pooled and analyzed by western blot for the detection of 
HNF4α (PP-H1415-00, R&D Biosystems). 
 
3.5: Cell Culture: 
CHO cells were used for luciferase expression assays. These cells were cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS, Omega Scientific, Tarzana, CA), 1% penicillin/streptomycin, and L-proline 
(50 µg/mL). Caco-2, HT-29, and SW620 cells were used for analyzing FXR expression 
by real-time PCR, FXR promoter CpG island methylation, and siRNA knockdown 
experiments for DNA methylation studies. Caco-2 and HT-29 were cultured in DMEM 
and SW620 cells were cultured in Leibovitz’s L-15 media, both supplemented with 10% 
FBS and 1% penicillin/streptomycin. Caco-2 and HT-29 cells were incubated in a 
humidified 37oC incubator with 5% CO2, whereas SW-620 cells were incubated in a 
humidified 37oC incubator with 0% CO2. 
 
3.5.1: Plasmid constructs, transfection and lucifer ase expression assays. 
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Fragments containing an FXRRE (IR-1), in the promoter and downstream 
regulatory regions of the Nr0b2 gene were amplified and cloned upstream of the 
luciferase gene into firefly luciferase vector pGL4.23[luc2/minP] (Promega, Madison, 
WI) as previously reported (Li et al., 2010). An active HNF4α binding site upstream of 
Baat gene TSS has already been previously reported (Inoue et al., 2004) and was used 
as positive control for HNF4α transcriptional activity. For this study, this region was 
amplified from mouse genomic DNA by PCR using pairs of primers containing XhoI and 
HindIII restriction enzyme sites, and cloned into the pGL4.23 firefly luciferase vector. 
The sequences of the primers are: forward 5’- 
CACAACTCGAGAATGGCTAAGACTATAGAT-3’, and reverse 5’- 
CTGAGGAAGCTTTCTTAGTATTTCCCTCCTC-3’. The sequences of these constructs 
were confirmed by DNA sequencing. 
CHO cells were grown to 90% confluence in 12-well plates, and were transiently 
transfected with the various reporter gene constructs as well as pCMV-ICIS human FXR 
and/or pCMV-sport6 mouse HNF4α (Open Biosystems, Huntsville, AL), pSG5 human 
RXRα, and phRGTK-renilla luciferase vector (Promega, Madison, WI). Transient 
transfection was done using Turbofect (Fermentas, Inc., Glen Burnie, MD) according to 
the manufacturer’s instructions. Twenty-four hrs after transfection, cells were trypsinized 
and plated into 96-well plates and treated with 100 nM GW4064, 0.1% DMSO (control), 
or no treatment for HNF4α-alone groups. Twenty-four hours later, firefly luciferase and 
renilla luciferase activities were quantified using a Dual-Glo Luciferase Kit from 
Promega (Madison, WI) with a Synergy-HT plate reader (Bio-Tek Instruments, Inc., 
Winooski, VT). FXR/RXR expression vectors were co-transfected with increasing 
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amounts (3, 10, and 30 ng) of HNF4α expression vector with the addition of FXR 
synthetic ligand, GW4064. The Shp promoter and downstream IR-1s cloned into 
luciferase expression vectors were used to assess the effects of HNF4α on 
transcriptional activity of FXR. The transcriptional activity of increasing amounts of 
HNF4α expression vector (10, 50, and 100 ng) on the Shp promoter and downstream 
regulatory region, as well as a positive control gene, Baat, was also measured by 
luciferase assay. The firefly luciferase activity value was normalized as a ratio over 
renilla luciferase and expressed as firefly luciferase activity/renilla. The data are 
presented as the average of six wells and the experiments were repeated at least twice. 
 
3.5.2: Colon cancer cell lines and FXR expression. 
For analysis of FXR expression, HT-29, Caco-2, and SW620 cells were grown for 
3, 7, 14, and 21 days as previously reported (De Gottardi et al., 2004). RNA and DNA 
were then extracted as described below. The purified genomic DNA from these cells 
was used for bisulfite analysis and MeDIP, and RNA was prepared for real-time qPCR. 
 
3.5.3: Azacytidine treatment. 
As an initial screen, cDNAs prepared from 11 different colon cancer cell lines 
treated with a clinically used DNMT inhibitor, azacytidine (AZA, Sigma, St. Louis, MO), 
were used to measure mRNA levels of FXR by real-time qPCR. Complimentary DNAs 
were obtained from Dr. Vadevil Ganapathy from Georgia Health Sciences University. To 
confirm these preliminary results, colon cancer cell lines, HT-29 and SW620, were 
treated with AZA and mRNA levels of FXR were measured by real-time qPCR.  
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Complimentary DNA from these samples was prepared from 1 million cells were plated 
in 10-cm plate treated with or without 2 µg/ml azacytidine for three days. COL1A2 and 
FXR mRNA levels were determined by real-time qPCR. The COL1A2 gene encodes for 
the collagen-a2 protein and has been shown to be methylated in colon cancer cell line 
SW620 (Sengupta et al., 2003). Therefore, the expression of this gene in response to 
AZA treatment was used as a positive control. 
 
3.6: Human Colon Cancer Samples and FXR Expression.  
Two sets of human colon specimens were used to analyze mRNA levels of FXR 
and FXR target genes by real-time qPCR. One set was cDNA prepared from normal 
and cancerous colon tissues obtained from OriGene Technologies (Rockville, MD). The 
patient sample pathology reports can be obtained from OriGene’s website 
(http://www.origene.com; HCRT501). The second sample set was from the 
Biospecimen Core of the Cancer Center in the University of Kansas Medical Center. 
The patient sample pathology report for this set is listed in Table 2 . In addition, cDNA 
prepared from human colon cancer cells lines HT-29, NCM460, KM12L4, Colo201, 
SW620, and LS-174T were obtained from Dr. Vadevil Ganapathy from Georgia Health 
Sciences University. Briefly, cells 1 million cells were plated in 10-cm plates in normal 
growth media, grown for 3 days, and RNA was extracted. RNA extraction and real-time 
qPCR protocols for human colon specimens are described below. All prepared cDNA 
was used to measure mRNA levels of FXR, OSTα, and OSTβ. Messenger RNA levels 




3.7: MeDIP Assay: 
The MeDIP assay was preformed as previously published (Weber et al., 2005). 
Specifically, HT-29 and SW620 cells were plated at 1 million cells in 10-cm plate and 
grown for 3 days in regular cell culture growth medium. Genomic DNA was extracted 
and purified as described below. Around 4 µg of sheared DNA was diluted into 450 µl of 
TE buffer, denatured in boiling water for 10 mins and immediately cooled on ice for 10 
mins. Next, 50 µl of 10x immunoprecipitation (IP) buffer (100 mM Na-Phosphate pH 7.0, 
1.4 M NaCl, 0.5% Triton X-100) and 50 ng of the 5-methylated-cytosines (5mC) 
antibody (MAb-335MEC-100, Diagenode Inc., Sparta, NJ) were added to the DNA 
solution and samples were incubated overnight at 4oC with overhead shaking. Magnetic 
Dynabeads (Invitrogen, M-280 sheep anti-mouse IgG) were pre-washed with PBS + 
0.1% BSA for 5 mins at room temperature with shaking. Beads were collected with a 
magnetic rack and resuspended with 40 µl of 1x IP buffer. DNA samples with anti-5mC 
antibody were added to the beads and incubated with overhead shaking at 4oC for 5 hrs. 
Beads were washed two times with 1x IP buffer for 10 mins at room temperature with 
shaking. Beads were resuspended in 250 µl proteinase K digestion buffer (50 mM Tris 
pH 8.0, 10 mM EDTA, 0.5% SDS) and 7 µl of proteinase K (10mg/ml) and incubated at 
50oC for 3 hours with shaking. Immunoprecipitated DNA was phenol/chloroform purified 
and dissolved in TE buffer. 
Precipitated DNA was analyzed by qPCR using primers designed to amplify 
positive control methylated CpG islands within the collagen-a2 promoter (Sengupta et 
al., 2003) and FXR promoter CpG island by SYBR green chemistry. Primers used to 
amplify these CpG island are: FXR CpG forward 5’- 
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GTTTGAGACAAGCCTGGGCAACAT-3’, and FXR CpG reverse 5’-  
ATTTCGGGTTCAAGCGGTTCTCCT-3’; COL1A2 CpG forward 5’-
TGCAGACAACGAGTCAGAGTTTCC-3’, and COL1A2 CpG reverse 5’- 
GGGCTGGCTTCTTAAATTGGTTCC-3’. Primers designed to amplify a non-  
methylated housekeeping gene (UBE2B) were used as a negative control and 
sequences are as previously reported (Sorensen et al., 2010). 
 
 
3.8: Bisulfite Sequencing: 
  Genomic DNA was isolated from human colon cancer cell lines, Caco-2, HT-29, 
and SW620, by standard DNA extraction protocols. Bisulfite conversion of genomic 
DNA was performed using EZ DNA Methylation Kit (Zymo Research Corporation, Irvine, 
CA).  
Six predicted CpG islands were identified in the FXR gene determined by 
MethPrimer (http:// www.urogene.org/methprimer/; Li and Dahiya, 2002). Figure 6a 
shows the relative locations of these predicted CpG islands as well as the locations of 
each CpG island from the FXR gene TSS. The CpG islands found upstream of tumor 
suppressor gene TSS are considered the most common site of methylation for gene 
silencing (Baylin et al., 1998). Therefore, only the CpG island located upstream of FXR 
TSS was investigated for methylation. Primers specific for bisulfite converted DNA were 
used to amplify this CpG island located upstream of FXR TSS. The bisulfite specific 
primers used to amplify converted FXR promoter CpG island were: forward 5’-





Figure 6:   
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Figure 6: Predicted CpG islands within the FXR ( NR1H4) gene. a) There are 6 
predicted CpG islands within the FXR gene as determined by MethPrimer CpG island 
predictor software. CpG island A is located approximately -3.2 to -2.9 Kb upstream of 
the TSS and CpG island B is located around 1.85 to 2.45 Kb downstream of the TSS, 
within the first intron of the FXR gene. CpG islands C, D, E, and F are located at 
approximately 24.4 to 24.9, 42.35 to 42.85, 59.85 to 60.35, and 87 to 87.5 Kb 
downstream of the TSS, within the 3rd, 4th, 5th, and 9th introns of the FXR gene. CpG 
island A is shown as a dashed line and CpG sites illustrated as black circles. b) The 
predicted sequence of FXR promoter CpG island (CpG island A) after bisulfite 
sequencing assuming complete CpG methylation. There are 11 predicted CpG sites 




CTATCACCTAAACTAAAAAACAATAA -3’. After PCR amplification, fragments were gel 
purified and cloned into a TOPO TA vector (Invitrogen, Carlsbad, CA). The bisulfite 
converted CpG island clones were then purified and sequenced using ACGT, Inc. 
(Wheeling, IL) sequencing services. Bisulfite sequencing will convert non-methylated 
cytosine to uracil, but will be unable to convert 5-methylated cytosine. Sequencing of  
bisulfite converted DNA reveals the presence of methylated CpG sites within this CpG 
island. There are 11 predicted CpG sites within the FXR promoter CpG island. Figure 
6b shows the predicted sequence of this CpG island after bisulfite conversion. Bisulfite 
sequencing was done on genomic DNA extracted from Caco-2, HT-29, and SW620 that 
were grown for 3, 7, 14 and 21 days. Data are reported as percent methylation of the  
CpG island found within the FXR gene promoter, or number of confirmed CpG sites out 
of 11 predicted CpG sites. 
 
3.9: SiRNA Knockdown: 
  DNMT 1 and 3B are enzymes commonly associated with aberrant DNA 
methylation (Jones and Baylin, 2002; Rhee et al., 2002). Therefore, to assess whether 
DNMT 1 and/or 3B are responsible for FXR gene methylation in SW620 resulting in 
FXR down-regulation, siRNAs designed to knockdown expression of DNMT1 or 
DNMT3B were used. The smartpool siRNAs for knockdown of these two DNMTs and 
non-targeting siRNA were obtained from Dharmacon (Lafayette, CO). SW620 cells were 
plated at 30% confluence and reverse-transfected with DMNT 1, DNMT 3B, or non-
targeting siRNAs using Turbofect (Fermentas, Inc.) for 96 hrs. DMNT 1 and 3B 
knockdown was confirmed by real-time PCR analysis before determining endpoints. 
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After knockdown of DNMT 1 and/or 3B, total RNA were prepared. RNA was used to 
quantify mRNA levels of FXR and positive control gene for DNMT inhibition, COL1A2. 
 
3.10: RNA Extraction and Real-Time qPCR:  
  Total RNA was isolated from mouse ileum and colon, human colon samples, and 
colon cancer cells lines using Trizol reagent according to the manufacturer’s instructions 
(Invitrogen, Carlsbad, CA, USA). Complimentary DNA was prepared by standard RT-
PCR methods using random primers (Fermentas, Inc.). Mouse tissues were used to 
measure FXR mRNA in ileum and colon and cDNA prepared from human colon 
samples and cell lines were used to measure mRNA levels of FXR, SHP, OSTα, and/or 
OSTβ. Complimentary DNA prepared from SW620 cells used in DNMT siRNA 
knockdown experiments were used to measure mRNA levels of DNMT 1, DNMT 3B, 
FXR, and the positive control gene, COL1A2. All real-time qPCR reactions were done 
using standard SYBR green chemistry and an ABI Prism 7900 Detection system 
(Applied Biosystems, Foster City, CA). The mRNA levels of these genes were 
normalized to 18s mRNA levels for the mouse samples and β-actin or GAPDH for the 
human samples. The primer sequences used for real-time qPCR are listed in Table 3 .  
 
3.11: Genomic DNA Extraction for MeDIP and Bisulfit e Sequencing:   
Genomic DNA was extracted from human colon cancer cell lines Caco-2, HT-29, 
and SW620 for MeDIP and bisulfite sequencing as previously described (Sengupta et 
al., 2003; Weber et al., 2005). Specifically, cancer cells were harvested then 
resuspended in DNA lysis buffer (10mM Tris (pH 7.5), 10mM EDTA, 10mM NaCl , 0.5%  
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Table 3: Real-time qPCR primers.  
Primer Name  Forward  Reverse  
Mouse    
FXRα CTTGATGTGCTACAAAAGCTGTG ACTCTCCAAGACATCAGCATCTC 
FXRβ CATACAAGGGCTAATGAAGTTTACCA TTTTGACGCCTTCTGTAATGC 
18S CCGAAGCGTTTACTTTGAAAAAA TTCATTATTCCTAGCTGCGGTATC 
Human    
FXR TGCATTGAAGTTGCTCTCAGGT CGCCTGACTGAATTACGGACA 
SHP AGCTGGAAGTGAGAGCAGATCC AGAAGTGCGTAGAGAATGGCG 
Ostα CTACACCTGGGTGAGCAGAA AGAGGAATAGGGAGGCGAAC 
Ostβ GCAGCTGTGGTGGTCATTAT TAGGCTGTTGTGATCCTTGG 
DNMT 1 TGTACCGAGTTGGTGATGGTGTGT TGCTGCCTTTGATGTAGTCGGAGT 
DNMT 3B ATTGTTTGATGGCATCGCGACAGG ACAGCAATGGACTCCTCACACACT 
GAPDH GGTGGTCTCCTCTGACTTCAA GTTGCTGTAGCCAAATTCGTTGT 
 
 
sodium dodecyl sulfate) and 1mg/ml Proteinase K and incubated at 55OC for 5 hours or 
overnight. Ethanol was added to precipitate DNA, DNA was collected, washed with 75% 
ethanol, and redissolved into DNase free water. Genomic DNA was further purified by 
standard phenol/chloroform extraction methods. Purified DNA was briefly sonicated to 
fragment the genomic DNA, and then column purified using standard PCR purification 
kits (Fermentas). Purified, fragmented genomic DNA was then used for MeDIP and 
bisulfite sequencing analysis. 
 
3.12: Western Blot:  
For western blot analysis of co-IP samples, 15 µg of whole cell input protein 
lysate and total FXR IP fractions (40 µl) were loaded onto a 12% acrylamide/Tris-HCL 
gel and electorphoresed 45 mins at 190 millivolts (mV). Protein was then transferred to 
0.45 µm PVDF membrane for 60 mins at 100 mV. Blots were labeled with antibody 
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against HNF4α (PP-H1415-00, R&D Biosystems) overnight and then detected by 
standard chemiluminescent detection methods (ECL, Amerisham/ GE Healthcare 
Biosciences, Pittsburg, PA). 
 
3.13: Statistical Analysis:  
Statistical analysis was done using Student’s t-test and p-value < 0.05 was 
considered statistically significant. The groups compared are listed as the following. For 
ChIP-qPCR analysis, agonist treated or KO animals were compared to vehicle treated 
WT controls. For HNF4α-alone luciferase assays, CHO cells transfected with luciferase 
vector containing response elements were compared to luciferase vector control. For 
luciferase assays with HNF4α and FXR, GW4064 treated CHO cells with FXR-RXR 
alone were compared to DMSO treated control cells and cells with increasing amounts 
of HNF4α vector with GW4064 treatment were compared to CHO cells with FXR-RXR 
and GW4064. For animal studies, ileum and colon from APCmin mice were compared to 
those from WT control mice. Human colon cancer samples from stages I, II, III, and IV 
were compared to normal human colon samples. For AZA treated colon cancer cell 
lines, cells treated with AZA were compared to vehicle treated cells. For MeDIP analysis, 
PCR reactions done to amplify CpG islands were compared to a negative control region, 
as well as MeDIP from SW620 cells compared to that of HT-29 cells. For SiRNA 
knockdown experiments, SW620 cells transfected with DNMT 1 or 3b siRNAs were 










 FXR is a bile acid-activated TF belonging to the nuclear receptor superfamily. 
FXR is highly expressed in liver and intestine, and cross-talk mediated by FXR in these 
two organs is critical in maintaining bile acid homeostasis. FXR deficiency has been 
implicated in many liver and intestine diseases. However, regulation of transcription by 
FXR at genomic level is not known. This study analyzed genome-wide FXR binding in 
liver and intestine of mice treated with a synthetic FXR ligand (GW4064) by ChIP-seq. 
The results showed a large degree of tissue-specific FXR binding, with only 11% of total 
sites shared between liver and intestine. The sites were widely distributed between 
intergenic, upstream, intragenic, and downstream of genes, with novel sites identified 
within even known FXR target genes. Motif analysis revealed a half nuclear receptor 
binding site adjacent to the FXR response element, IR-1, indicating the involvement of 
other TFs for modulating FXR binding and/or function. Furthermore, pathway analysis 
indicated that FXR may be extensively involved in multiple cellular metabolic pathways. 
Conclusion: This study reports genome-wide FXR binding in vivo and the results clearly 
demonstrate tissue-specific FXR/gene interaction. In addition, FXR may be involved in 






FXR, highly expressed in liver and intestine, is a ligand-activated TF belonging to 
the nuclear receptor superfamily. FXR was adopted when bile acids were identified as 
its endogenous ligands (Forman et al., 1995; Parks et al., 1999). FXR is essential in 
maintaining bile acid homeostasis and is important for energy balance through 
regulating lipid and glucose metabolism (Lambert et al., 2003; Ma et al., 2006; Sinal et 
al., 2000). FXR deficiency in mice has been implicated not only in hepatic and 
gastroenterological diseases, such as cholestasis, gallstones, NAFLD, liver and 
intestinal carcinogenesis, but also in systemic metabolic abnormalities such as 
atherosclerosis (Guo et al., 2006; Kong et al., 2009; Moschetta et al., 2004; Yang et al., 
2007).  
As a TF, FXR induces gene transcription by directly binding to an IR-1, as a 
heterodimer with the RXRα, in promoters of target genes including Nr0b2, Abcb11, 
Ibabp, Osta and Ostb (Laffitte et al., 2000). However, direct binding of FXR homodimer 
to promoter of Apoa1, encoding APOA-I, suppresses gene transcription (Claudel et al., 
2002). FXR also suppresses gene transcription indirectly via induction of SHP (encoded 
by Nr0b2), an orphan nuclear receptor with only a ligand- but not a DNA-binding domain. 
SHP suppresses transcription through interactions with other TFs (Goodwin et al., 2000; 
Lu et al., 2000). FXR has emerged as a critical factor in mediating crosstalk between 
the liver and intestine to maintain bile acid, lipid and glucose homeostasis. Activation of 
FXR in the intestine induces Fgf 15/FGF 19 which travels to the liver to suppress the 
transcriptional activation of Cyp7a1 that encodes a rate-limiting enzyme in bile acid 
synthesis (Inagaki et al., 2005; Kim et al., 2007; Song et al., 2009).  
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Despite the importance of FXR in regulating liver and intestine pathophysiology, 
a complete understanding of FXR-DNA interaction at the genomic level is not known. 
Several studies have identified transcriptional profiles in liver and intestine with FXR 
activation and/or deletion by microarray analysis (Downes et al., 2003; Inagaki et al., 
2006; Xing et al., 2009). However, this approach cannot elucidate direct FXR binding. In 
addition, many in vitro FXR binding studies were performed in cell lines not of hepatic or 
intestinal origin. Instead, FXR was over-expressed in an artificial cellular environment 
and the promoters used to investigate FXR binding activity were outside of their natural 
chromatin context. Thus, many binding sites for a TF in living cells could be masked by 
the presence of a non-permissive chromatin environment, and therefore, the assays 
would reveal a false positive binding at these sites. New techniques have been 
developed to identify genomic binding sites of TFs. These techniques are ChIP followed 
by either the hybridization of the immunoprecipitated DNA pool to a tiling array (ChIP-
chip) or by end-sequencing of millions of immunoprecipitated DNA fragments (ChIP-
seq). ChIP-chip data tend to have low resolution and are often quite noisy (Johnson et 
al., 2008), and therefore, even with certain challenges, ChIP-seq is a better tool for 
analyzing genome-wide binding of TFs (Park, 2009). ChIP-seq has already been 
applied for quantitatively detecting nuclear receptor binding sites in a genome-wide 
manner (Nielsen et al., 2008). 
In the current study, we have used ChIP-seq analysis to determine genome-wide 
FXR binding sites, in both the mouse liver and intestine. The results not only revealed 
novel binding sites for FXR, but also implicated new patterns of transcriptional 
regulation. This work highly suggests novel mechanism(s) by which FXR regulates 
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4.3.1: Determine the optimal time point of FXR/DNA binding in vivo following 
ligand treatment. 
Due to the dynamic nature of TF-DNA binding, we first determined the optimal 
time point for FXR/DNA binding following treatment with GW4064 for 2, 4 or 8 hrs. In 
liver, FXR is known to bind to the promoter of the Nr0b2 gene (Holt et al., 2003). 
Conversely, in intestine, FXR binds to FXRREs in the promoter regions of Osta and 
Ostb genes (Lee et al., 2006). Therefore, initial ChIP-qPCR assays were performed to 
amplify known FXRREs in Nr0b2 (-320 to -220 bp upstream of TSS) for liver samples 
and Osta (-1245 to -1145 bp upstream of TSS) and Ostb (-220 to -150 bp upstream of 
TSS) for intestine samples. In both liver and intestine samples, binding of FXR to known 
FXRREs was strong and independent of GW4064 treatment when compared to 
untranscribed regions (Untr6), which serves as a negative control (Figure 7a and 7b). 
This confirms the specificity of both the FXR binding and the FXR antibody. Based on 
these results, only samples from GW4064-treated mice were used for ChIP-seq 
analysis. Liver samples with 4 hr GW4064 treatment and intestine samples with 2 hr 
GW4064 treatment showed relatively stronger FXR binding, thereby were used for 












Figure 7: Initial validation of FXR binding to know n FXRREs by ChIP-qPCR.  
Predicted FXRREs are found at -320 to -220 bp upstream of Nr0b2 TSS in the liver, -
1245 to -1145 bp upstream of TSS of Osta and -220 to -150 bp upstream of Ostb in the 
intestine. Primers were designed to amplify these specific sites. The graphs are 
displayed as number of binding events detected per 1000 cells (y-axis) versus a specific 
amplified site (x-axis). a) Illustrates FXR binding at -320 to -220 bp upstream of Nr0b2 in 
the liver of mice treated with vehicle or GW4064 for 2, 4, or 8 hrs. b) Illustrates FXR 
binding at -1245 to -1145 bp upstream of Osta and -220 to -150 bp upstream of Ostb in 
the intestine of mice treated with vehicle or GW4064 for 2, 4, or 8 hours. These ChIP-
qPCR results show FXR binding at these sites is higher than for untranscribed regions 
of the genome (Untr 6). This indicates that the assay and the anti-FXR antibody used 
are specific to detect FXR bound regions of the genome. The greatest enrichment factor 
of GW4064 treated mice versus vehicle control is 1.59 (seen for Osta in the intestines 
for the 8 hr treatment group). These results indicate that FXR binding at these target 
sites is not sufficiently enhanced after treatment of animals with an FXR ligand.  
Therefore, only tissues from animals treated with GW4064 were used for ChIP-seq 





Table 4:  Previously reported FXR binding sites det ected by ChIP-Seq. 
 
Gene Binding Site Peak Value Tissue 
Nr0b2  -320 to -220 bp bp 
upstream of TSS 
258; 124 liver; intestine 
Abcb11  -240 to -140 bp 
upstream of TSS 
308 liver 
Fgf15 1880-1980 bp with in 
an intron 
43; 273 liver; intestine 
Osta  -1245 to -1145 bp 
upstream of TSS 
502 intestine 
Ostb  -220 to -150 bp 
upstream of TSS 
271; 572 liver; intestine 
Fabp6  
site 1: -220 to -120; 
site 2: -2990 to -2890;  
and site 3: -7600 to -
7500 bp upstream 




4.3.2: Validation of FXR binding sites discovered b y ChIP-seq. 
To validate the ChIP-seq results, novel FXR binding sites were randomly chosen 
for confirmation by ChIP-qPCR assay. In the ChIP-seq data set, the intensity of FXR 
binding to DNA was reported as peak value. Many known FXRREs previously identified 
were detected with relatively high peak values (Table 4 ). Based on peak values 
reported in ChIP-seq data, the sites listed in Table 4, together with other randomly 
selected novel sites, were categorized as having high (>300), medium (100-300), or low 
(<100) peak values and were tested by ChIP-qPCR, with gene names listed in Tables 5 
and 6. These sites were tested in liver only (20 sites), intestine only (5 sites), or in both 
tissues (27 sites). The results showed 100% of the sites with high, 84.4% with medium  
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Table 5:  List of genes validated after the ChIP-se q assay in the liver. 
 
Peak Value Genes Validated Genes not validated 
> 300 peak 
value 
Hmga1, Fcna (1), Fcna (2), 
Slc10a1 (2), Slc9a8, Pdgfrb, 
Pddc1, Sumo3, Tcfap2e, 
Cks2, Mirn126 (2), Nr0b2 (1), 




Mir499, Rarres2, Stat2, 
Caprin1, Cdk5rap2, Actg1, 
Vkorc1, Mirn126 (1), Cnnm3 
(1), Nat2, IL17b, Pcx (1), Ldha 
(2), Bccip 





Cebpb, Gtf2a2, Ell2, Fga-(1), 
Igfals, Tlr3, Trmp7, Gpbp1 (1) 
Cdh 15, Slc10a1 
(1), Fga (2), Ldha 
(1), Cnnm3 (2) 
 
Note: (1) and (2) indicate two sites identified in one gene. 
 
 
Table 6:  List of genes validated after the ChIP-se q assay in the intestine. 
 
Peak Value Genes Validated Genes not validated 
> 300 peak 
value 
Slc25a3, Slc22a21, Slc9a8, 
Pddc1, Cks2, Tlr3, Pcx (1), 
Ldha (2), Mirn126 (2), Fgf15, 




Plat, Nr0b2 (1), Actg1, 
Cdk5rap2, Sumo3, Caprin1, 
Mirn126 (2), Cnnm3 (1), Nrld2, 









Note: (1) and (2) indicate two sites identified in one gene. 
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  Peak Value %Confirmation    
27 genes >300 100 (27/27) 
32 genes 100-300 84.4 (27/32) 
20 genes <100 70 (14/20) 
 
 
and 70% with low peak values were confirmed (Table 7 ). All together, 86% (68/79) of 
the sites were verified by ChIP-qPCR as true FXR binding sites. Based on these results, 
we concluded the ChIP-seq results are relatively accurate. Therefore, more detailed 
analysis of the ChIP-seq results was performed. 
 
4.3.3: Analysis of genome-wide FXR binding sites in  liver and intestine. 
There were a total of 7794 FXR binding sites in liver and 5321 in intestine. 
However, 6345 sites were found specifically in liver, 3872 specifically in intestine, and 
1449, representing 11% of total sites, were bound by FXR in both tissues (Figure 8a ). 
The FXR binding sites were widely distributed throughout the mouse genome. Forty-
one % of total FXR binding sites in liver, and 39% in intestine, were located more than 
10 kb upstream of a RefSeq gene (intergenic regions). Conversely, 59% of the total 
sites in liver and 61% in intestine were found directly associated with a gene, indicating 
that FXR binding in both liver and intestine is more highly concentrated within coding 
regions of the mouse genome. Of these binding sites: 1% in liver and intestine overlap 
with 5’-untranslated regions (5’UTRs); 4% in liver and 3% in intestine were located in 








Figure 8: Total FXR binding sites in liver and inte stine. a) A venn diagram of total 
FXR binding in liver (red), intestine (blue), or both (green). b) Percentage of FXR 
binding sites in liver and intestine that were distributed to >10 kb from genes (intergenic), 
< 10 kb upstream of genes, introns, exons, 5’UTRs, 3’UTRs, and < 10 kb downstream 




1% in liver and intestine overlap with 3’UTRs; and 10% in liver and intestine were 
located within10 kb downstream of genes (Figure 8b ).   
Many genes were bound by FXR at multiple regions, including upstream, in-gene, 
and downstream of genes, including known FXR target genes previously identified to 
have only one FXRRE. For example, multiple FXR binding sites were identified for 
Nr0b2 and Ostb (Figure 9a and 9b ). Therefore, the total number of genes to which FXR 
bound was less than the total number of binding sites. There were 4248 genes in liver 
and 3406 genes in intestine to which FXR was shown to bind at a single or multiple 
regions. Among them, 1713 genes were shared by both liver and intestine.  
The average peak value of FXR binding sites was higher for sites within 10 kb 
upstream of TSSs, and the frequency of binding (number of binding events) was higher 
for binding sites located near the TSS of target genes in both liver and intestine (Figure 
10a). The average peak value decreased with distance from proximal promoter and 
frequency of binding decreased with the distance from the TSSs. In addition, there was 
a relatively high percentage of intron binding of FXR (Figure 8b ). Therefore, the 
genome-wide intron binding of FXR was further evaluated for cumulative binding events 
of FXR within intron regions in the liver and intestines (Figure 10b ). Most of the intron 
binding of FXR was in close proximity to TSSs of target genes, with 1107 peaks from 
both tissues falling within the first intron of a gene [640 peaks in the liver (red) and 467 












Figure 9: Histogram of novel FXR binding sites with in known FXR target genes, 
Nr0b2 and Ostb. The y-axis displays the peak value and the x-axis shows the 
chromosomal location of the gene. The top panel (displayed in red) represents FXR 
binding in liver, and the bottom panel (displayed in blue) represents FXR binding in 
intestine. Genes that are displayed above the chromosome scale are oriented in the 
sense directions (right arrow), and genes that are displayed below the chromosome 
scale are oriented in the anti-sense direction (left arrow). The threshold is set at peak 
value > 20.  a) The Nr0b2 gene is located on chromosome 4 (Chr4): 133109305-
133112451 and is oriented in the sense direction in this figure. FXR binds at 2 locations 
around the Nr0b2 gene in intestine, promoter region (peak value = 124) and 3’ end of 
the gene (peak value = 381). FXR binds at 4 locations of the Nr0b2 gene in liver, 2 in 
the promoter and 2 at the 3’ end (peak values are 69, 258, 498, and 49, respectively). b) 
The Ostb gene is located at Chr9: 65260560-65270580 and is oriented in the anti-sense 
direction. In intestine, FXR binds at 4 locations near the Ostb gene, with 3 sites within 
the promoter (peak value = 572, 27, and 210) and 1 located at the 3’ end (peak value= 
132). In liver, FXR binds once within the promoter (peak value = 271) and once at the 3’ 
end (peak value = 44). Novel FXR sites found at the 3’ end of both Nr0b2 and Ostb 









Figure 10: Distribution of total FXR binding sites relative to TSSs and intron 
binding of FXR. a) The top panel is the frequency distribution of FXR binding, showing 
the number of binding events (y-axis) at each distance from TSSs (x-axis). The bottom 
panel displays average peak value of binding sites at each distance from TSSs. The y-
axis displays the average peak value and the x-axis shows the distance of binding site 
from the TSS. The highest number of FXR binding events was greatest at the TSSs of 
genes, and the average peak value of FXR binding sites was greatest within 10 kb 
upstream of TSSs of genes. b) The cumulative binding events of FXR distributed only to 
introns of genes in the liver (red) and intestine (blue). The graph displays the total 
number of FXR binding peaks (y-axis) in the liver and intestine located within intron 1-31 
of genes (x-axis). There were a higher number of peaks within the first intron of genes 




4.3.4: Novel FXR binding sites revealed by ChIP-Seq . 
FXR was found to bind to many novel sites within the mouse genome. For 
example, FXR bound to several sites within the first intron of the Nr1i2 gene, which 
encodes PXR (highest peak value: 654 in liver and intestine, indicated by ‘*’; Figure 
11a). A novel FXR binding site was also discovered at a 3’ regulatory region of the 
Nr0b2 gene (peak value: 498 in liver and 381 in intestine, indicated by ‘*’; Figure 9a ). 
Binding of FXR to this site in the liver has been confirmed by regular ChIP-qPCR 
(Figure 5b ).   
FXR has been shown to up-regulate both OSTα and β (encoded by Osta and 
Ostb respectively) in liver and intestine (Boyer et al., 2006; Lee et al., 2006). This has 
been previously recorded as being a result of direct FXR binding to regulatory regions of 
Osta and Ostb genes in both liver and intestine (Landrier et al., 2006). The current study 
confirmed the binding of FXR in intestine to upstream regions of Osta and Ostb (Figure 
11b: Osta and Figure 9b : Ostb). In addition, in liver FXR bound to upstream regions of 
Ostb (Figure 9b ). However, these results clearly showed that FXR did not bind to 
regulatory regions of Osta in liver (Figure 11b ). Furthermore, binding of FXR to 3’ end 
of Ostb and to the proximal promoter and intron region of Osta in the intestine has not 
been previously reported (indicated by ‘*’). The present results also showed FXR bound 
directly to two upstream regulatory regions of Slc10a1, which encodes Ntcp, in liver with 
relatively high intensity (peak value: 50 at -150 to -50 bp and 300 at -8100 to -8000 bp), 
which are uncharacterized FXR binding sites (indicated by ‘*,’ Figure 11c ). Ntcp is a 
bile acid uptake transporter essential for hepatic uptake of conjugated bile acids. ChIP-









Figure 11: Histogram of novel FXR binding sites wit hin Nr1i2, Osta, and Slc10a1. 
a) The Nr1i2 gene is located on Chr16: 38248437-38294909 and is oriented in the anti-
sense direction. Previously uncharacterized FXR binding sites were found at multiple 
regions within the Nrli2 gene indicated by ‘*’ (the brackets include all FXR binding sites 
in the 1st intron of the gene). These binding sites were located within the promoter 
region and introns 1 and 2 of the gene (highest peak value was 646 in liver and 654 in 
intestine). b) The Osta gene is located on Chr16: 32475664-32487965 and is oriented in 
anti-sense direction. FXR binds to Osta in the intestine but not in the liver, displaying 
tissue-specific binding. Binding of FXR to promoter region (-1245 to -1145 upstream of 
TSS) of Osta in the intestine has been previously characterized, and serves as a 
positive control for our analysis (peak value = 502). However, binding of FXR within -
100 bp upstream of TSS (peak value = 70) and within intron 2 of Osta in the intestine 
are novel findings (peak value = 333; indicated by ‘*’). c) The Slc10a1 gene is located 
on Chr12: 82056479-82068971 and is oriented in the anti-sense direction. FXR binds at 
2 sites in the Slc10a1 promoter in liver (around -100 bp and -8000 bp upstream of TSS, 
peak value = 38 and 304, respectively; indicated by ‘*’). Binding of FXR to these sites 
were confirmed by ChIP-qPCR (data not shown).  
76 
 
(data not shown). The histograms of Osta and Slc10a1 clearly show tissue-specific DNA 
binding of FXR, with Osta only being bound in intestine (Figure 11b ) and Slc10a1 only 
being bound in liver (Figure 11c ).   
 
4.3.5: Motif analysis of FXR binding sites. 
As mentioned earlier, the most characterized FXRRE is an IR-1. This motif has 
been found within many known FXR target genes, including Nr0b2, Fabp6 (encodes 
Ibabp) and Fgf15/FGF19. In the current study, the most common motif identified was an 
IR-1 (Figure 12 ). In this analysis, the different sized nucleotides represent the 
probability of the represented nucleotide being located at a specific location. The larger 
nucleotides represent a higher probability of the motif containing that nucleotide 
sequence and therefore are considered more significant. Interestingly, a half nuclear 
receptor binding site, AGGTCA, was found adjacent to the IR-1 at the 3’ end in the liver. 
Conversely, the most commonly occurring sequences for intestine FXR binding sites 
were an IR-1 and an everted repeat separated by 2 nucleotides (ER-2). As with the liver 
samples, there was a half site adjacent to the FXR binding sites in intestine. However, 
the half site could be at the 3’ end (TGACCT) if FXR binding site was an ER-2 or at the 
5’ end (TGACCT) if FXR binding site was an IR-1. Nevertheless, the motif analysis 
suggests tissue-specific sequence motifs to which FXR recognizes and binds.  
 
4.3.6: Biological pathway analysis. 
FXR is essential in regulating pathways important for bile acid, lipid, and glucose 









Figure 12: Motif analysis. Three most commonly identified sequence motifs of the top 
500 FXR binding sites in the liver (top panel) and intestine (bottom panel) are shown 
according to MEME analysis. In the liver, an IR-1 was the most common sequence motif 
found. Two of the three motifs identified (left and right motif) in the liver showed the 
presence of a half nuclear receptor binding site at the 3’ end of the IR-1. In the intestine, 
an IR-1 (left motif) or an ER-2 (middle motif) were motifs commonly found within the top 
500 FXR binding sites. The motifs found in the intestine are arbitrarily aligned to match 
up with the sequence motifs in the liver to show sequence similarity. In the intestine, a 
half nuclear receptor binding site was also associated with the identified FXRRE either 
at the 5’ end (half site 1) or at the 3’ end (half site 2), depending on which motif is 





Table 8:  Pathways enriched with FXR binding 2 kb u p-stream of genes in liver. 
 




primary metabolic process 92 93.9 1.70E-25 8.80E-22 
cellular metabolic process 88 89.8 1.90E-20 9.60E-17 
biosynthetic process 38 38.8 7.60E-16 4.00E-12 
cellular biosynthetic process 25 25.5 5.60E-09 2.90E-05 
nitrogen compound metabolic 
process 
25 25.5 4.90E-17 2.60E-13 
amine metabolic process 24 24.5 1.40E-16 5.80E-13 
amino acid and derivative 
metabolic process 
24 24.5 3.80E-18 2.00E-14 
amino acid metabolic process 23 23.5 3.20E-19 1.70E-15 
lipid biosynthetic process 21 21.4 8.90E-17 5.80E-13 
steroid metabolic process 18 18.4 7.50E-17 5.80E-13 
monosaccharide metabolic 
process 
11 11.2 3.80E-08 1.90E-04 
hexose metabolic process 11 11.2 3.10E-08 1.60E-04 
sterol metabolic process 11 11.2 4.50E-11 2.30E-07 
cholesterol metabolic process 11 11.2 1.70E-11 8.80E-08 
glucose metabolic process 10 10.2 2.80E-08 1.50E-04 
lipid catabolic process 10 10.2 2.40E-08 1.20E-04 
fatty acid oxidation 8 8.2 1.30E-10 7.00E-07 
steroid biosynthetic process 7 7.1 6.30E-06 3.20E-02 
glycine, serine and threonine 
metabolism 
7 7.1 1.20E-04 2.30E-02 
isoprenoid metabolic process 7 7.1 8.70E-08 4.50E-04 
pyruvate metabolic process 7 7.1 8.40E-09 4.30E-05 
pyruvate metabolism 6 6.1 5.60E-04 1.00E-01 
amino acid biosynthetic 
process 
6 6.1 7.80E-06 4.00E-02 
glycerol ether metabolic 
process 
6 6.1 1.30E-06 6.80E-03 
glycerolipid metabolic process 6 6.1 1.10E-06 5.70E-03 
neutral lipid metabolic process 6 6.1 1.10E-06 5.70E-03 
acylglycerol metabolic process 6 6.1 9.20E-07 4.80E-03 
sterol transport 6 6.1 9.50E-08 4.90E-04 
cholesterol transport 6 6.1 7.00E-08 3.60E-04 
triacylglycerol metabolic 
process 
5 5.1 9.80E-06 4.90E-02 
gluconeogenesis 5 5.1 6.50E-06 3.30E-02 
cholesterol homeostasis 5 5.1 5.20E-06 2.70E-02 
lipid homeostasis 5 5.1 5.20E-06 2.70E-02 
sterol homeostasis 5 5.1 5.20E-06 2.70E-02 
 




other biological pathways not been previously recognized. To further determine 
biological pathways that may be regulated by FXR, genes bound by FXR less than 2 kb 
upstream of their TSSs were selected for biological pathway analysis. Functional  
Annotation analysis revealed FXR may be involved in several metabolic pathways in 
liver (Table 8 ). In fact, 90% of genes categorized into the cellular metabolism process 
were bound by FXR in the liver. Furthermore, FXR may also be significantly involved in 
regulating other pathways that are not known to be regulated by FXR, such as amino 
acid and nitrogen compound metabolism.  
In intestine, however, FXR seems to regulate different pathways than in liver. For 
example, FXR binds to 40% of the genes categorized in the catalytic pathway 
processes, suggesting FXR may be highly involved in regulating catalytic pathways in 
the intestine. In addition, pathways involved in oxidoreductase activity, monooxygenase 
activity, and cofactor binding seemed to be highly enriched with FXR binding in intestine 
(Table 9 ). Interestingly, pathways involved in intestinal inflammation, such as 
complement and coagulation cascades, are also enriched with FXR binding.   
 
 
4.4: Concluding Remarks: 
In the current study, genome-wide FXR binding sites were analyzed by ChIP-seq 
analysis in both liver and intestine following treatment of mice with a potent synthetic 
FXR ligand. The current study not only summarizes binding sites for FXR within the 
mouse genome in liver and intestine, but also suggests potential tissue-specific patterns 




Table 9:  Pathways enriched with FXR binding 2 kb u p-stream of genes in 
intestine. 
 






catalytic activity 283 40.8 2.20E-16 6.00E-13 
oxidoreductase activity 64 9.2 2.30E-07 6.20E-04 
generation of precursor 
metabolites and energy 
46 6.6 2.40E-07 1.20E-03 
electron transport 36 5.2 9.90E-06 5.00E-02 
iron ion binding 30 4.3 3.10E-06 8.40E-03 
cofactor binding 24 3.5 1.30E-07 3.40E-04 
vitamin binding 19 2.7 1.70E-08 4.60E-05 
monooxygenase activity 17 2.4 1.00E-05 2.80E-02 
complement and coagulation 
cascades 14 2 9.70E-05 1.90E-02 
unspecific monooxygenase 
activity 9 1.3 2.10E-05 5.50E-02 
 
Note: * indicates the number of genes bound by FXR in this pathway 
 
The initial validation study by regular ChIP-qPCR assay showed that in vivo FXR 
appears to bind to its response element in the regulatory region of FXR target genes, 
presumably due to activation by endogenous ligands (bile acids). The binding intensity 
has been slightly enhanced upon treatment with a potent synthetic ligand, GW4064. 
Thereby treatment with GW4064, a ligand with higher affinity for FXR than bile acids 
(Maloney et al., 2000), may result in an endogenous-to-synthetic ligand switch. In 
agreement with this notion, previous in vitro studies using HepG2 cells, which are 
known to synthesize bile acids, have shown that FXR binds to its response element 
weakly in the presence of control vehicle, and treatment with various synthetic ligands 
enhanced the binding (Fang et al., 2008). Furthermore, we also observed a weak FXR 
interaction with its response element in the mouse hepatoma cell line, Hepa1c1c cells, 
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and this interaction was enhanced upon treatment with GW4064 (data not shown). 
Collectively these results may indicate a ligand switch for FXR.   
To further validate the ChIP-seq data, we have also applied a different peak 
finding algorithm to our data set. We have been using MACS (Zhang et al., 2008). It 
looks for local enrichments of alignments that show the correct orientation that would be 
expected for a ChIP peak (peak modeling). It thus eliminates at least some false 
positives. The analysis from the MACS showed that of the 7796 liver peaks (intervals) in 
the original analysis, 6942 (89.05%) were also identified by MACS, and of the 5324 
original Ileum peaks, 5023 (94.35%) were also identified by MACS. 
Using the ChIP-seq discovery approach, DNA regions bound by FXR have been 
identified throughout the entire mouse genome. This study shows a novel FXR binding 
pattern with novel FXR binding sites located large distances upstream (intergenic), 
downstream, or within genes (intragenic). In fact, this study shows a large portion of 
FXR binding sites are located more than 10 kb away from a RefSeq gene. This 
indicates long-distance chromatin interactions as a possible mechanism for FXR-
mediated regulation of gene transcription (Li et al., 2004). However, the majority of FXR 
binding sites are concentrated within coding regions of the mouse genome. Of these 
sites, FXR is highly associated with the proximal promoter and first intron. Recent ChIP-
tiling array and ChIP-seq reports on other nuclear receptors and TFs have also revealed 
a high percentage of intergenic binding (Gao et al., 2008; Lupien et al., 2008; Nielsen et 
al., 2008). In addition, a previous report of genome-wide ERα binding has also shown a 
higher intensity of binding near the TSSs of genes, which is consistent with this study 
(Gao et al., 2008).   
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This study exhibits a high degree of tissue-specific binding sites for FXR as well 
as a tissue-specific binding pattern, with a relatively low portion of total sites shared 
between liver and intestine. For example, Nr0b2, a classical FXR target gene encoding 
SHP, is expressed at a much higher level in liver than in intestine (Kamisako et al., 
2007). In both tissues, SHP expression levels can be strongly induced through 
activation of FXR. The current study reveals that FXR binds with high intensity to a 
downstream IR-1 of the Nr0b2 gene in both liver and intestine. Furthermore, FXR also 
binds to other known target genes, including Osta, Ibabp, and Slc10a1 in a tissue-
specific manner. Ibabp and Osta are bound by FXR in intestine but not in liver, which, 
for Osta, is in contrast with a previous report that FXR also binds to the promoter region 
of Osta in liver (Boyer et al., 2006). Likewise, the Slc10a1 gene, encoding Ntcp, has two 
FXR binding sites within promoter regions in liver.  Ntcp has been shown to be 
suppressed by high concentrations of bile acids under cholestatic conditions through an 
FXR-SHP mediated mechanism (Zollner et al., 2005). However, the finding of FXR 
binding sites in the Slc10a1 promoter region suggests that FXR may directly regulate 
the transcription of the Slc10a1 gene. Furthermore, tissue-specific FXR regulation of 
these genes may be mediated by tissue-specific cofactors or chromatin modification.    
The motif analysis indicates the most represented FXR binding motif in mouse 
liver is an IR-1, which has been indentified in many FXR target genes. In mouse 
intestine, an IR-1 was also the most commonly represented motifs; however, an ER-2 
motif was also represented as a possible FXR binding sequence. In addition, there was 
a half nuclear receptor binding site adjacent to the FXR binding site in both liver and 
intestine. The motif analysis suggests there are tissue-specific sequence motifs to which 
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FXR recognizes and binds. In addition, this new finding indicates a potential interaction 
between FXR and other orphan nuclear receptors/TFs known to bind to this half site (Ito 
et al., 2000). These cofactors may be important for modulating transcriptional activation 
of FXR target genes. The interaction between hormone nuclear receptors and other TFs 
have been previously reported. For example, ERα has been shown to interact with 
FOXA1 for optimal DNA binding and transcriptional activation (Lupien et al., 2008). 
The current study also suggests that FXR may directly regulate more diverse 
biological pathways. For example, FXR binds to Rara and Rorc and may regulate 
transcriptional activation of these genes as well as retinol and hormone metabolism 
(data not shown). This means that FXR not only regulates bile acid and lipid 
homeostasis, but may also be directly involved in other cellular functions. In addition, 
FXR may regulate bile acid and lipid homeostasis to a greater extent than previously 
determined. Further studies are needed to characterize the significance of FXR’s 
involvement in these pathways to clarify networks controlled and shared by FXR to 
maintain cellular and organ homeostasis.   
In summary, this study analyzed genome-wide FXR-DNA binding in both the 
mouse liver and intestine following ligand treatment. The identification of novel FXR 
binding sites, as well as unique binding patterns, enable a more profound understanding 





Chapter 5: FXR and HNF4 α Interact to Cooperatively Regulate Gene Transcript ion 
in the Liver 
 
5.1: Abstract: 
HNF4α is a nuclear receptor critical for regulating liver development, 
differentiation and function. FXR is also a ligand-activated nuclear receptor critical for 
liver function. Studies show mice deficient in FXR develop cholestasis, hyperlipidemia 
and liver tumors. The old paradigm suggests linear activation of target gene 
transcription following direct binding of FXR to gene regulatory regions. However, we 
showed that FXR activated gene transcription by cooperating with HNF4α to regulate 
gene transcription in the liver. Data obtained from ChIP-seq analysis of mouse livers 
showed nearly 50% of FXR binding sites in liver overlapped with HNF4α binding sites. 
In addition, the majority of FXR and HNF4α binding sites were close in proximity. Co-IP 
assays imply that FXR may directly interact with HNF4α. Furthermore, luciferase assays 
suggest an interaction of HNF4α and FXR leads to a modest additive effect on FXR-
mediated transcriptional activation. In conclusion, this study shows initial evidence of a 






FXR is a ligand-activated TF belonging to the nuclear receptor superfamily. FXR 
is classified as a group II nuclear receptor and bile acids are its endogenous ligands 
(Makishima et al., 1999; Parks et al., 1999; Wang et al., 1999). FXR is highly expressed 
in the liver and intestine and is a master regulator of the enterohepatic circulation of bile 
acids at the transcriptional level (Kok et al., 2003; Sinal et al., 2000; Zhang et al., 2003). 
FXR has also been shown to regulate other metabolic processes such as lipid 
homeostasis, glucose metabolism, insulin sensitivity, and liver/colon cancer 
development, and therefore is a potential therapeutic target for the treatment or 
prevention of cholestasis, hyperlipidemia, fatty liver, type II diabetes, and liver and colon 
cancer (Cariou et al., 2006; Claudel et al., 2003; Kim et al., 2007; Ma et al., 2006; 
Modica et al., 2008; Staels and Kuipers, 2007; Watanabe et al., 2004; Yang et al., 2007; 
Zhang et al., 2006). Recent genome-wide binding studies have shown that FXR 
displays a high degree of tissue-specific binding (Thomas et al., 2010). In addition, motif 
analysis of genome-wide FXR binding in liver revealed a half nuclear receptor binding 
site associated with the FXRRE, which is an IR-1 (Chong et al., 2010; Thomas et al., 
2010).  These studies suggest the involvement of other orphan nuclear receptors in 
regulating FXR function.  
HNF4α is a highly conserved orphan nuclear receptor and linoleic acid has been 
shown to occupy the LBD of HNF4α (Sladek et al., 1990; Yuan et al., 2009) but does 
not affect transcriptional activity of HNF4α (Yuan et al., 2009). HNF4α is critical for liver 
development, differentiation, and organism survival (Chen et al., 1994). In hepatocytes, 
HN4α localizes mainly to the nucleus, binds DNA exclusively as a homodimer, and 
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recognizes response elements consisting namely of DR-1 (Gonzalez, 2008). HNF4α 
regulates the expression of a myriad of liver-specific genes including production of 
clotting factors, apolipoprotein synthesis, and drug metabolism (Gonzalez, 2008). In 
addition, HNF4α has been shown to directly regulate the transcription of Cyp7a1 and 
Cyp8b1, enzymes responsible for bile acid synthesis, as well as the expression of other 
genes critical for bile acid metabolism suggesting HNF4α is also important in regulating 
bile acid homeostasis (Crestani et al., 1998; Inoue et al., 2006; Stroup and Chiang, 
2000). In fact, hepatocyte-specific deletion of HNF4α  in mice leads elevated serum bile 
acid levels (Hayhurst et al., 2001). 
FXR and HNF4α have already been shown to regulate the expression of the 
same genes such as apolipoprotein C-III (APOC-III), CYP7A1, and bile acid-CoA: amino 
acid N-acyltransferase (BAAT; Claudel et al., 2003; Inoue et al., 2004; Inoue et al., 
2006; Shih et al., 2000), thereby, suggesting an overlap of FXR and HNF4α function in 
the liver. However, a study investigating how FXR and HNF4α interact in the liver on a 
genome-wide scale to regulate gene transcription is lacking.  
It has been suggested that FXR constitutively sits on FXRREs within target 
genes as a heterodimer with RXRα. In the absence of bile acids, this FXR-RXRα dimer 
associates with corepressors to repress gene transcription. Upon binding of bile acids, 
the FXR-RXRα heterodimer releases corepressors and recruits coactivators and 
subsequently initiates transcription of FXR target genes (reviewed by Modica et al., 
2010). As mentioned above, genome-wide binding studies have shown that FXR 
displays a high degree of tissue-specific binding (Thomas et al., 2010). This study 
showed that genes bound by FXR in liver differ vastly from those bound in the intestine 
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implicating the involvement of other tissue-specific factors responsible for organizing the 
binding of FXR. Motif analysis of FXR binding sites in liver showed a nuclear receptor 
half site highly associated with the FXRRE (IR-1) suggesting an orphan nuclear 
receptor may coordinate FXR binding and function (Chong et al., 2010; Thomas et al., 
2010). Further studies revealed liver receptor homolog-1 (LRH-1) is capable of binding 
to this half site and could be an important nuclear receptor responsible for mediating 
tissue-specific function of FXR, although this may not be the only orphan nuclear 
receptor capable of binding to this specific half site (Catalano et al., 2010; Chong et al., 
2010; Wilson et al., 1992). On a different note, studies have shown that the orphan 
nuclear receptor HNF4α is capable of enhancing the liver-specific functions of other 
type II nuclear receptors. For example, HNF4α has been shown to cooperatively 
enhance the transcriptional activity of CAR and PXR at the CYP3A4 promoter (Tirona et 
al., 2003). However, the effects of HNF4α on FXR activity are largely unknown. 
Therefore, we hypothesize that HNF4α interacts with FXR to enhance FXR function in 
the liver. In the current study we have compared the genome-wide binding of FXR and 
HNF4α in mouse livers and characterized cooperation between these two factors on 
binding to target gene DNA and on regulating gene transcription. 
 
5.3: Results:  
5.3.1: ChIP-sequencing.   
Genome-wide binding of FXR and HNF4α in mouse livers from previous reports 









Figure 13: Genome-Wide binding of FXR and HNF4 α in mouse liver. a) Venn 
diagram of total HNF4α and FXR binding sites in mouse livers as revealed by ChIP-seq 
analysis. There were 10917 total Hnf4α binding sites and 7797 total FXR binding sites 
mouse liver, of which 3882 binding sites are shared between both factors. b) Histogram 
of the binding frequency, or number of binding events, of HNF4α (y-axis) in relation to 
distance from FXR binding site (x-axis) at shared target genes in mouse livers. FXR 




shows a venn diagram of total FXR and HNF4α binding sites in mouse livers. There 
were 10917 total Hnf4α binding sites and 7797 total FXR binding sites mouse liver, of 
which 3882 binding sites are shared between both factors. These results show 49.7% of 
total FXR binding sites co-localize with HNF4α. Next, the frequency, or number of 
binding events (y-axis), of HNF4α binding to shared target genes in relation to distance 
from FXR binding site (x-axis) was determined. These results showed HNF4α and FXR 
do not bind to same site, but rather the frequency of HNF4α binding was greatest when 
bound upstream and in close proximity to FXR (FXR binding site is represented by “0”; 
Figure 13b ). Pathway analysis of direct target genes shared by FXR and HNF4α are 
presented in Table 10 . Pathways involving compliment and coagulation cascades from 
this analysis had the highest number of genes targeted by FXR and HNF4α. The list of 
shared target genes categorized by Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway maps as being a part of complement and coagulation cascades, along 
with locations of FXR and HNF4α binding sites from gene TSS and relative binding 
counts of each factor are listed in Table 11. 
Figure 14a is a histogram of binding of FXR (red) and HNF4α (black) to the Shp 
gene (Nr0b2) in mouse livers, generated by UCSC Genome Browser 
(http://genome.ucsc.edu; Kent et al., 2002). As can be seen, both the promoter and 
downstream FXR binding sites within the Shp gene co-localized with those of HNF4α. 
Sequence analysis of these regions by NUBIScan (Podvinec et al., 2002) showed a 
classical HNF4α binding site, DR-1, located in the promoter of the Shp gene but not the 




Table 10: Pathways enriched by both FXR and HNF4 α binding in mouse liver. 
Pathway Genes* 




Complement and coagulation cascades 17 2.24 1.38E-07 2.25E-05 
Drug metabolism 16 2.11 8.33E-07 1.36E-04 
PPAR signaling pathway 16 2.11 1.67E-06 2.73E-04 
Metabolism of xenobiotics by cytochrome P450 13 1.71 2.97E-05 4.83E-03 
Insulin signaling pathway 12 1.58 4.55E-02 0.999 
Glycine, serine and threonine metabolism 9 1.18 6.15E-05 9.97E-03 
Steroid hormone biosynthesis 9 1.18 7.58E-04 0.116 
Adipocytokine signaling pathway 9 1.18 9.80E-03 0.799 
Pyruvate metabolism 8 1.05 2.07E-03 0.287 
Fatty acid metabolism 8 1.05 3.59E-03 0.443 
Drug metabolism 8 1.05 5.19E-03 0.572 
Retinol metabolism 8 1.05 3.20E-02 0.995 
Cysteine and methionine metabolism 7 0.92 3.10E-03 0.397 
Linoleic acid metabolism 7 0.92 1.61E-02 0.929 
Biosynthesis of unsaturated fatty acids 6 0.79 6.32E-03 0.644 
Starch and sucrose metabolism 6 0.79 2.13E-02 0.970 
ABC transporters 6 0.79 4.99E-02 1.000 
Selenoamino acid metabolism 5 0.66 1.80E-02 0.948 
Alanine, aspartate and glutamate metabolism 5 0.66 4.36E-02 0.999 
Primary bile acid biosynthesis 4 0.53 2.74E-02 0.989 
 
Note: * indicates the number of genes bound by FXR and HNF4α in this pathway 
 
 
IR-1, was previously identified in both of these regions (Li et al., 2010; Thomas et al., 
2010) 
 
5.3.2: ChIP-qPCR.  
Binding sites that were co-localized by both FXR and HNF4α in mouse livers 
were analyzed by ChIP-qPCR analysis for binding of HNF4α in WT and FXR KO mouse 
livers treated with or without GW4064. Binding site locations and counts of FXR and  
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Table 11: List of FXR and HNF4 α shared target genes categorized within 
complement and coagulation cascades.  
 
Gene Name Distance from TSS  FXR Counts  HNF4α Counts  
Plg -144, 1992, 6986, 9608 99, 155, 127, 95 46, 39, 31, 33 
Fga -225, -5561 150, 105 40, 53 
Cpb2 -9013, 9 52, 34 38, 19 
Serpina1e -4534 , 3769 76, 35 62, 27 
Fgg -345, -4534, 1904, 2607 70, 197, 20, 28 9, 47, 26, 25 
F2 -436 129 67 
Mbl1 -44, 9558 192, 156 24, 64 
Cfh 21 109 21 
Kng2 -125, -10481  69, 40 39, 17 
Serpine1 -507 115 33 
Cfb -183 217 78 
Serpinf2 -66 41 22 
C4b -17142 93 83 
C2 -4 68 46 
C3 -236, -2276, -2788, -5187 884, 75, 69, 175 46, 15, 10, 55 
Proc -1366 77 53 




HNF4α binding to a few selective shared target genes reveal by ChIP-seq analysis are 
summarized in Table 12 and were investigated for HNF4α binding. ChIP-qPCR results  
showed HNF4α binding to shared target genes, Apoc3, Baat, Nr0b2, and Sqstm1 was 
increased in WT mouse livers treated with an FXR agonist, GW4064 (Figure 14b , top). 
Likewise, HNF4α binding to Apoc3, Baat, and 5’ and 3’ regulatory regions of Nr0b2 









Figure 14: Histogram of binding of FXR and HNF4 α to Nr0b2 (Shp) gene and ChIP-
qPCR analysis. a) Histogram of the binding of FXR (black) and HNF4α (red) to the 
Nr0b2 (Shp) gene in mouse livers as determined by ChIP-seq analysis. Histogram was 
generated using UCSC genome browser (http://genome.ucsc.edu; Kent et al., 2002). b) 
Binding of HNF4α to shared target genes, Nr0b2, Sqstm1, Apoc3, and Baat in WT 
mouse livers treated with or without GW4064 (top) or in WT and FXR KO livers (bottom) 
analyzed by ChIP-qPCR analysis. Results are reported as fold change over IgG 




Table 12: FXR and HNF4 α binding sites from ChIP-seq analysis.  
 
Gene Name Distance to TSS FXR Counts  HNF4α Counts 
Apoc3 -8 94 127 
Baat -107 19 29 
Nr0b2 -436 520 193 
Nr0b2 4079 771 57 
Sqstm1 13061 669 22 
 
 
5.3.3: Co-IP.  
Co-IP assays were carried out on whole cell liver isolates extracted from WT and 
FXR KO mice fed diets with or without 1% CA. Lysates were immunoprecipitated using 
an antibody against FXR, and then IP fractions were analyzed by western blot labeling 
for HNF4α. Using this analysis, a weak FXR-HNF4α protein-protein interaction was 
detected in WT mice fed control diet (Figure 15a ). This interaction increased in the 
livers of mice fed 1% CA diet was nearly undetectable in livers of FXR KO mice (Figure 
15a).  
 
5.3.4: Luciferase activity.  
HNF4α binding to Nr0b2 promoter and downstream regulatory region was 
detected by ChIP-seq analysis. These binding sites were analyzed for HNF4α 
transcriptional activity by using luciferase reporter assays. Transcriptional activity of  
HNF4α on Baat gene promoter has already been characterized (Inoue et al., 2004) and 
was used as a positive control. These results show that HNF4α significantly increased 











Figure 15: Co-IP of FXR and HNF4 α and luciferase assays. a) Co-IP of WT mouse 
livers fed control diet or 1% CA diet, and FXR KO mouse livers fed control diet. Whole 
cell liver lysates were prepared and immunoprecipitated using antibody against FXR. 
Liver lysates (input) and IP fractions were analyzed by western blot analysis using 
antibody against HNF4α. b) Luciferase expression assays showing the effects of 
increasing concentrations of mouse HNF4α expression vector on transcriptionally 
activating regulatory regions in Baat  gene, 5’ region of Nr0b2 gene, and 3’ region of 
Nr0b2 gene (top). Bottom panel shows the effects of increasing mouse HNF4α 
expression vector concentrations on FXR induced transcription of 5’ and 3’ regions of 
Nr0b2 gene after activation of FXR with GW4064. Results are reported as ratio of firefly 




manner, but not the downstream regulatory region of Nr0b2 (Figure 15b , top, * p < 
0.05).  
Next, the effect of HNF4α on the transcriptional activity of FXR at both the 
promoter and downstream regulatory region of Nr0b2 was analyzed by luciferase 
reporter assay. The ability of FXR to transcriptionally regulate the promoter and 
downstream regulatory region of the Shp gene has already been previously reported (Li 
et al., 2010). Our results confirm that FXR significantly increases transcriptional activity 
of both of these sites (Figure 15b , bottom, * p < 0.05). In addition, at low concentrations 
(3 ng of expression plasmid) HNF4α increased the transcriptional activity of FXR at the 
3’ regulatory region of Shp nearly 2-fold, although this increase was not found to be 
statistically significant. However, HNF4α did not increase transcriptional activity of FXR 
at the Shp promoter. In fact, it appears there was a slight decrease in transcriptional 
activity.  
 
5.4: Concluding Remarks:  
FXR is a type II adopted nuclear receptor and bile acids are its endogenous 
ligands (Makishima et al., 1999; Parks et al., 1999). As mentioned, FXR’s most well 
characterized role is in regulating the enterohepatic circulation of bile acids. However, 
FXR has also been shown to regulate a variety of metabolic processes such as lipid 
homeostasis, glucose metabolism, insulin sensitivity, and liver and gastrointestinal 
cancer development (Cariou et al., 2006; Claudel et al., 2003; Kim et al., 2007; Ma et al., 
2006; Modica et al., 2008; Staels and Kuipers, 2007; Watanabe et al., 2004; Yang et al., 
2007; Zhang et al., 2006). Because of the profound role FXR plays in these processes, 
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it has become a very promising therapeutic target for the treatment or prevention of 
cholestasis, hyperlipidemia, fatty liver, type II diabetes, and liver and colon cancer. 
Genome-wide binding studies have shown that FXR has a very high degree of tissue-
specific binding and suggests the involvement of orphan nuclear receptors in regulating 
FXR function (Chong et al., 2010; Thomas et al., 2010). HNF4α is an orphan nuclear 
receptor shown to regulate a large array of liver-specific functions. In addition, HNF4α 
regulates several aspects of bile acid metabolism suggesting possible overlapping 
function with FXR (Inoue et al., 2004). Furthermore, HNF4α has been shown to 
cooperatively enhance liver-specific gene transcription of two other type II nuclear 
receptors, CAR and PXR (Tirona et al., 2003). Therefore, we hypothesize that HNF4α 
also functions to cooperatively regulate the function of FXR in the liver. 
In order to accomplish this, FXR and HNF4α ChIP-seq data in mouse livers were 
re-analyzed to determine the degree of overlapping binding of these two factors. Even 
though this analysis was done from different animals, the results showed that nearly 
50% of FXR binding sites in liver overlapped with those of HNF4α including co-
localization of HNF4α with FXR to both the promoter and downstream regulatory 
regions of the Nr0b2 gene that encodes Shp. Of the binding sites that were shared by 
both factors, the binding frequency of HNF4α was highest when the binding site was 
located upstream and in close proximity to the FXR binding site. These results suggest 
that the function of FXR highly correlates with HNF4α function and implicates a possible 
protein-protein interaction suggested by close proximity of binding. Pathway analysis 
showed FXR and HNF4α target genes are highly enriched within complement and 
coagulation cascades and drug metabolism suggesting these may be the pathways 
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cooperatively regulated by FXR and HNF4α. ChIP-qPCR analysis determined that 
HNF4α binding to shared target genes, including the promoter and downstream 
regulatory regions of Nr0b2, increased in mouse livers treated with an FXR agonist, 
GW4064, and decreased in FXR KO mouse livers, suggesting a cooperative and 
dependent effect of HNF4α binding with FXR. These preliminary results indicate HNF4α 
binding to these shared target genes is dependent on the presence and function of FXR. 
Preliminary ChIP-qPCR was also done in livers of WT and hepatocyte-specific HNF4α 
KO mice and the effects of FXR binding to shared target genes were analyzed. These 
results showed no difference in FXR binding to Apoc3 and Nr0b2 in hepatocyte-specific 
HNF4α KO livers, and therefore it appears FXR binding to these sites is not dependent 
on HNF4α binding (data no shown). However, more extensive studies need to be 
completed in order to experimentally test this hypothesis. For example, binding of FXR 
in conditional HNF4α KO mice livers treated with an FXR agonist would need to be 
done to fully evaluate cooperative binding. 
Next, co-IP analysis revealed a weak FXR and HNF4α protein-protein interaction 
in WT mouse livers. This interaction was enhanced in livers of WT mice treated with an 
FXR agonist, and nearly eliminated in FXR KO mice, confirming an FXR-induced 
interaction with HNF4α. Finally, luciferase assays showed the HNF4α binding site within 
the Nr0b2 promoter, but not the downstream binding site, contains a putative DR-1 and 
is transcriptionally active. Conversely, HNF4α moderately enhanced transcriptional 
activity of FXR at the downstream regulatory region of Nr0b2, but not the promoter. 
However, it should be noted that the total effect of HNF4α activity on FXR function may 
not be fully represented in a luciferase expression assay. This is because HNF4α may 
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be interacting with FXR to stabilize chromatin microenvironment around the Nr0b2 gene, 
which is a process not properly reflected in an artificial expression assays. To illustrate 
this, a study has shown that the 5’ and 3’ binding pattern of FXR at the Nr0b2 gene 
functions to mediate a head-to-tail chromatin loop around the Nr0b2 gene (Li et al., 
2010). This may be an essential process required for the efficient transcription of the 
Shp gene in response to FXR activation. ChIP-seq data demonstrated that HNF4α also 
co-localizes with FXR to 5’ and 3’ binding sites of the Nr0b2 gene, therefore, suggesting 
that HNF4α may be important for mediating FXR induced head-to-tail chromatin loop 
around the Nr0b2 gene. 
Other studies have implicated that FXR and HNF4α have opposite effects on 
gene transcription of shared target genes. For example, Apoc3 is a well characterized 
HNF4α target gene and HNF4α haploinsufficiency, or decreased hepatic expression of 
HNF4α, is associated with decreased serum apoC-III levels, therefore, suggesting 
HNF4α functions to increase transcription of Apoc3 (Shih et al., 2000; Sladek et al., 
1990) . However, FXR has been shown to inhibit the transcription of Apoc3 by binding 
to the promoter region of this gene (Claudel et al., 2003). Nevertheless, the 
transcriptional effect of HNF4α and FXR on shared targets genes on a genome-wide 
scale was previously unknown. This study suggests that these two factors have an 
overall cooperative effect on gene transcription of target genes rather than an opposite 
effect. 
In conclusion, we have revealed a high prevalence of co-localization of FXR 
binding to HNF4α binding in mouse livers, including to 5’ and 3’ regulatory regions of 
the Shp (Nr0b2) gene. In addition, co-IP and luciferase assays suggest FXR and 
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HNF4α interact at the protein level and this interaction moderately increases 
transcriptional activity of FXR at the Shp gene. Therefore, we have determined that FXR 









High-fat diets increase intestinal exposure to bile acids, thereby, increasing the 
risk of colon cancer. FXR is a bile acid nuclear receptor critical for minimizing intestinal 
injury from bile acids. Studies have shown that FXR deficiency in mice promotes colon 
cancer development, indicating FXR as a tumor suppressor. This study showed that 
human colon cancer samples and a mouse model for intestinal cancer, APCmin mice, 
had decreased expression of FXR. Likewise, expression of FXR in colon cancer cell 
lines was inversely related to cancer cells’ malignancy. No genetic mutations within the 
FXR gene or its promoter were found to account for the difference in FXR expression or 
function in colon cancer cell lines. However, when treated with a clinically used DNMT 
inhibitor, AZA, human colon cancer cell lines had a marked increase in FXR mRNA, 
suggesting DNA methylation as a mechanism for FXR silencing in colon cancer. Using 
bisulfite sequencing and MeDIP analysis, methylation of a FXR promoter CpG island 
was confirmed in human colon cancer cells and the degree of methylation was inversely 
correlated to FXR expression. Finally, siRNA knockdown of DNMT1 and 3B in the colon 
cancer cell line SW620 increased FXR expression, suggesting these enzymes are 
responsible for aberrant FXR gene methylation. In conclusion, this study has 
determined that FXR expression is decreased in human colon cancer, further 
suggesting it as a tumor suppressor, and the mechanism of down-regulation is, in part, 




Colon cancer is the third most common cancer and the third leading cause of 
cancer related deaths in the United States. Two major risk factors for colon cancer 
development are diets high in saturated fat and low in fiber (Armstrong and Doll, 1975).  
Dietary fats are emulsified by bile acids in the intestine in order for proper digestion and 
absorption. However, high fat diets leads to an elevated intestinal bile acid load, and low 
dietary fiber increases the gastrointestinal transit time (Correa, 1981; Willett et al., 1990).  
Together these factors increase both level and time of bile acid exposure.   
In the distal ileum and colon, primary bile acids are converted to secondary bile 
acids by intestinal microflora (Hofmann, 1999). Secondary bile acids, DCA and LCA, are 
considered to be more cytotoxic compared to primary bile acids, CA and CDCA, due to 
their detergent-like properties and higher hydrophobicity (Hofmann, 1999). DCA and 
LCA can induce colonic epithelium cytotoxicity through oxidative stress and promote cell 
proliferation, and therefore, are linked to increased colon carcinogenesis (Lechner et al., 
2002). In fact, it has been shown that patients with colorectal cancer have elevated 
levels of secondary bile acids in their feces (Bianchini et al., 1989; Hill et al., 1975; 
Reddy et al., 1978).  
FXR is a ligand-activated TF belonging to the nuclear receptor superfamily. FXR 
is highly expressed in liver and intestine and bile acids are its endogenous ligands 
(Forman et al., 1995; Parks et al., 1999). FXR critically regulates every aspect of the 
enterohepatic circulation of bile acids (Kok et al., 2003; Sinal et al., 2000). FXR 
functions to regulate the synthesis, transport, intestinal re-absorption, and free 
intracellular concentration of bile acids to prevent their accumulation to cytotoxic levels 
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(Inagaki et al., 2005; Okuwaki et al., 2007; Sinal et al., 2000; Tu et al., 2000; Zollner et 
al., 2006). Furthermore, FXR has been shown to attenuate the development of intestinal 
tumors in mouse models of colon cancer (Maran et al., 2009; Modica et al., 2008). This 
implicates FXR as a tumor suppressor for the development of colon cancer. However, 
the exact mechanisms of FXR induced tumor suppression are unknown. One suggested 
mechanism is through the protection of intestinal epithelium from bile acid toxicity by up-
regulating intracellular bile acid binding proteins and efflux transporters while down-
regulating bile acid influx transporters and de novo synthesis of bile acids. However, 
FXR appears to have anti-tumorigenic functions independent of its regulation of bile 
acid homeostasis. For example, FXR deficiency increases susceptibility to colon cancer 
development by increasing epithelial permeability to bacteria and promoting WNT/β-
catenin signaling as a result of TNFα released from infiltrating macrophages (Inagaki et 
al., 2006; Modica et al., 2008). 
FXR expression is inversely related to the malignancy of colon cancer cell lines, 
implicating colon cancer cells have developed a mechanism to selectively down-
regulate FXR (De Gottardi et al., 2004). Although polymorphisms within the FXR gene 
have been identified and associated with decreased function in intrahepatic cholestasis 
of pregnancy (ICP; Marzolini et al., 2007), no clinically known mutations exist within the 
FXR gene to explain decreased FXR expression or activity in human colon cancer.  
Therefore, it has been proposed that FXR expression is regulated by epigenetic 
mechanisms. DNA methylation is a common epigenetic mechanism involved in gene 
silencing. Cancer has been associated with an overall hypomethylation of genomic DNA, 
but hypermethylation of CpG islands located in promoter regions of tumor suppressor 
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genes (Baylin et al., 1998). A putative CpG island located just upstream of FXR gene 
(NR1H4) TSS was identified and proposed to be the site of DNA methylation 
responsible for FXR gene silencing in human colon cancer. This study was designed to 
determine the expression profile of FXR in human colon cancer and mouse intestinal 
cancer model and to test whether DNA methylation of the FXR promoter is responsible 
for FXR down-regulation in colon cancer. 
 
6.3 Results: 
6.3.1 FXR expression in intestinal carcinogen mouse  model.  
APCmin mice are a common intestinal carcinogen animal model (Su et al., 1992).  
Nearly 80% of all human colon cancers, inherited or sporadic, arise due to a mutation in 
the APC gene (Goss and Groden, 2000).This mouse model was used to investigate the 
expression levels of FXR in intestine. There are two isoforms of FXR, α and β, 
expressed in mouse ileum and colon (Zhang et al., 2003). Therefore, the expression of 
both of these isoforms was measured by real-time qPCR. These results show that 
mRNA levels of both isoforms of FXR were significantly decreased in the ileum and 
colon of 1-year-old APCmin mice, with a 3- and 11-fold decrease of isoforms α and β in 
ileum, and roughly 2.5-fold decrease of both isoforms in colon (Figure 16a , * p < 0.05). 












Figure 16: Relative expression of FXR and FXR targe t genes in APC min  mice, 
human colon cancer samples, and human colon cancer cell lines.  a) Relative 
mRNA levels of FXRα and FXRβ in ileum (left) and colon (right) of APCmin mice. b) 
Relative mRNA levels of FXR in two sample sets of human colon cancer samples (top), 
and relative mRNA levels of OSTα and OSTβ first sample set (bottom). c) Relative 
mRNA levels of FXR in non-metastatic colon cancer cell line HT-29 versus transformed 
or malignant/metastatic colon cancer cell lines, NCM460, KM12L4, Colo201, SW620, 




6.3.2 FXR expression in human colon cancers.  
In Figure 16b,  mRNA levels of FXR and FXR target genes OSTα and OSTβ, 
were down-regulated in all stages of colon cancer development. Decreased expression 
of these genes was not found to be statistically significant in this sample set, likely due 
to the low sample number included in this analysis.  
Messenger RNA levels of FXR were also measured in different colon cancer cell 
lines (Figure 16c ). These colon cancer cell lines differ in their degree of malignancy. 
HT-29 cells have been previously characterized as being a more differentiated colon 
cancer cell line, where as KM12L4, Colo201, SW620, and LS-174T cells have been 
described as more malignant colon cancer cell lines (De Gottardi et al., 2004; Leibovitz 
et al., 1976; Morikawa et al., 1988; Semple et al., 1978; Tom et al., 1976; Trainer et al., 
1988). NCM460 cells are a normal colonic epithelial cell line described as being non-
tumorigenic (Moyer et al., 1996). However, subcultures of cells have shown a 
transformed phenotype, abnormal karyotype and may be tumorigenic according to 
product information (Incell, San Antonio, TX). The results from this study showed that 
the expression profile of FXR differed in different colon cancer cell lines with mRNA 
levels of FXR inversely related to the malignancy of the colon cancer cell line. In order 
to determine if DNA mutation of the FXR gene (NR1H4) is responsible for decreased 
expression levels, the entire FXR gene and 5 kb upstream promoter were sequenced in 
Caco-2, HT-29, and SW620 cells, which have different basal expression levels of FXR. 
No mutations that could account for the difference in FXR expression levels in these 




6.3.3 Azacytidine treatment. 
Because no mutation was found in the FXR gene coding region in human colon 
cancer cells, epigenetic modification of the FXR gene are hypothesized to be 
responsible for the decreased FXR expression in colon cancer. In order to determine if 
DNA methylation was responsible for suppression of FXR gene expression, a panel of 
cDNAs prepared from 11 different colon cancer cell lines treated with a DNMT inhibitor, 
AZA, was used to measure mRNA levels of FXR. This preliminary screen revealed 6 out 
of 11 of these colon cancer cell lines showed a 1.7 to 233 fold increase in FXR 
expression after AZA treatment (Table 13 ). To confirm this, colon cancer cell lines HT-
29 and SW620, which have different basal expression of FXR and different responses 
to AZA as revealed by the original screen, were treated with AZA and then mRNA levels 
of FXR and COL1A2 (positive control gene known to be methylated in colon cancers) 
were measured (Figure 17a ). As mentioned, these colon cancer cell lines differ in their 
relative malignancy and differentiation, where HT-29 cells are considered more 
differentiated cells and SW620 cells more malignant (De Gottardi et al., 2004). This  
 
Table 13: FXR expression in colon cancer cell lines  after AZA treatment. 
 
Cell Line 
Fold Chg After AZA  
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Figure 17: Relative expression of FXR in human colo n Cancer cell lines treated 
with a DNMT inhibitor and MeDIP analysis of FXR pro moter CpG island.  a) Relative 
mRNA levels of FXR in HT-29 and SW620 cells treated with 2ug/mL of AZA for three 
days. b) Immunoprecipitation of genomic DNA from HT-29 and SW620 cells with 
antibody against 5-mC followed by qPCR analysis of immunoprecipitated DNA. 
Methylation of a CpG island located near COL1A2 TSS was analyzed as positive 
control, and an unmethylated genomic region was analyzed for the negative control. To 
determine the immunoprecipitation of predicted FXR promoter CpG island, primers were 




experiment showed that AZA treatment significantly increased mRNA levels of both 
FXR and COL1A2 in SW620 cells 6- and 8- fold (* p < 0.05), but not in HT-29 cells. 
Therefore, DNA methylation seems to be responsible for FXR gene suppression in  
SW620 cells, but not in HT-29 cells. Consequently, DNA methylation of the FXR gene 
was further investigated. In order to further determine whether DNA methylation of the 
FXR gene is responsible for suppression of FXR gene expression in human colon 
cancer, the FXR gene and 5 kb promoter sequence was analyzed for the presence of 
predicted CpG islands using MethPrimer (Li and Dahiya, 2002). As mentioned, 6 
predicted CpG islands were identified by this analysis (Figure 6a ). However, only 
methylation of the CpG island located in the promoter of FXR was analyzed in detail 
because this is typically the location of methylated CpG islands used for suppression of 
gene expression (Baylin et al., 1998). There are 11 predicted CpG sites located within 
this CpG island, as shown as a dashed line with the CpG sites are shown as black 
circles. The predicted sequence of this CpG island is shown in Figure 6b , with the 
dinucleotide CG underlined in the sequence. 
 
6.3.4 MeDIP analysis.  
Methylation of the FXR promoter CpG island was first analyzed by MeDIP 
analysis. This assay uses IP of genomic DNA using an antibody against 5-mC followed 
by qPCR analysis of IP DNA fragments. The MeDIP assay was done on genomic DNA 
isolated from HT-29 and SW620 cells. Identification of a methylated CpG island was 
first confirmed near the TSS of COL1A2 gene, which has been previously characterized 
in colon cancer cell lines (Sengupta et al., 2003). Likewise, a housekeeping gene region 
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found to not be methylated was used as a negative control for this assay (Sorensen et 
al., 2010). The results showed that, similar to the positive control with detectable levels 
of methylation of a CpG island located within a regulatory region of COL1A2, the CpG 
island within the FXR gene promoter had detectable methylation in both HT-29 and 
SW620 cells, around 400 and 600 fold over IgG, when compared to the non-methylated 
region (negative control), which was around 9 and 20 fold over IgG (Figure 17b ). 
Likewise, there seemed to be a slightly higher trend in COL1A2 and FXR promoter CpG 
island methylation in the SW620 cells, around 1.5 to 2 fold higher, than in HT-29 cells, 
although this is not statistically significant. 
  
6.3.5 Bisulfite treatment. 
MeDIP analysis is commonly used for the detection of methylated CpG islands 
but is insufficient in quantifying levels of methylation of these CpG islands. Therefore, to 
further characterize the degree and pattern of methylation of the confirmed CpG island 
within the FXR promoter, bisulfite sequencing analysis of this island was performed. In 
order to correlate level of CpG island methylation to the expression of FXR in colon 
cancer cell lines, HT-29, Caco-2, and SW620 cells were grown for 3, 7, 14, and 21 days 
and total RNA and genomic DNA were extracted. In all three cell lines, mRNA levels of 
FXR increased as cells grew to confluence, and reached maximal levels at day 14 
(Figure 18a ). At 21 days, FXR expression in HT-29, Caco-2, and SW620 either slightly 
decreased or leveled off. Genomic DNA was also collected from cells grown for 7, 14, 





Figure 18:   
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Figure 18: Relative expression of FXR and bisulfite  sequencing analysis of FXR 
promoter CpG island in colon cancer cell lines. a) Relative mRNA levels of FXR in 
HT-29, CaCO2, and SW620 cells grown 3, 7, 14, and 21 days. b) Bisulfite sequencing 
results of FXR promoter CpG island in HT-29, Caco-2, and SW620 cells grown 7, 14, 
and 21 days. Results are reported as the percentage of CpG island methylation, or 





percentage of CpG island methylation in the FXR promoter (Figure 18b ). Eight clones, 
generated from bisulfite conversion and PCR amplification, from each cell line grown for 
7, 14, and 21 days were sequenced and the number of methylated CpG sites out of 11 
total predicted CpG sites were calculated. Using this analysis, we were unable to detect 
any specific pattern of methylation in this CpG island which correlated with FXR 
expression. However, there was an inverse correlation of the percentage of FXR 
promoter methylation with FXR expression in Caco-2 and SW620, and only a slight 
correlation in HT-29. Specifically, Caco-2 and SW620 cells grown for 7 days, which had 
relatively lower levels of FXR mRNA, had increased percentage of FXR promoter CpG 
island methylation, around 87% and 72%. Conversely, at 14 days of growth, Caco-2 
and SW620 cells had decreased CpG island methylation of FXR promoter at 18% and 
0%, which correlates to maximal FXR mRNA levels in these cells. HT-29 cells 
maintained low levels of CpG island methylation, 22 and 14%, for cells grown both 7 
and 14 days, even though FXR mRNA levels changed from relatively lower levels at 7 
days to maximal levels at 14 days. At 21 days of growth, mRNA levels of FXR 
expression seemed to decrease or level off in HT-29, Caco-2, and SW620 cells. This 
was associated with an increase or mixed percentage of methylation of FXR promoter 
CpG island, at around 76%, 39%, and 45% for HT-29, Caco-2, and SW620 cells. 
Nevertheless, it appears that DNA methylation of FXR promoter CpG islands is 
associated with the difference in FXR expression seen in Caco-2 and SW620 cells, 
although this correlation was not as strong in HT-29 cells.  
 
6.3.6 SiRNA knockdown.  
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 SiRNA knockdown of DNMT 1 and 3B was done to determine the molecular 
machinery responsible for FXR down-regulation. SW620 cells have lower basal levels of 
FXR expression when compared to HT-29 cells, and responded to AZA treatment, 
therefore, these cells were used for DNMT siRNA knockdown. SW620 cells were 
transfected with siRNA designed to knockdown DNMT 1 or 3B, and RNA was extracted 
and analyzed for DNMT 1, DNMT 3B, FXR, and COL1A2 mRNA levels. Messenger 
RNA levels of these genes were normalized to mRNA levels of GAPDH. This study 
showed that knockdown of DNMT 1 and 3B, by nearly 80% (Figure 19a , * p < 0.05) 
were both sufficient to increase mRNA levels of FXR 6.7 and 7.3 fold, and positive 
control gene COL1A2 around 7 and 6.6 fold (Figure 19b ), although these values were 
not found to be statistically significant over non-targeting siRNA transfection controls. 
However, the increase in FXR and COL1A2 mRNA after DNMT 1 and 3B siRNA 
knockdown reach statistical significance or near significant levels when compared to the 
non-transfected control levels (statistical significance indicated by parenthesis, p-value 
< 0.05).  
 
6.4 Concluding Remarks: 
 Colon cancer is a significant health burden for the United States and its impact 
worldwide is increasing due to the adoption of western diet in developing countries. The 
high fat and low fiber components of the western diet have been highly associated with 
increased risk of colon cancer development (Armstrong and Doll, 1975; Correa, 1981). 







Figure 19:   
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Figure 19: SiRNA knockdown of DNMT 1 and 3B. SW620 cells were transiently 
transfected with siRNA designed to knockdown DNMT 1, 3B, or non-specific 
oligonucleotides. Knockdown was confirmed by real-time qPCR. a) Messenger RNA 
levels of DNMT 1 (left) and DNMT 3B (right) was nearly 80% that of the non-specific 
siRNA control. b) Relative mRNA levels of FXR (left) and COL1A2 (right) in SW620 
cells after siRNA knockdown of DNMT 1 and 3B. COL1A2 has been previously shown 
to be methylated in SW620 cells and, therefore was used as a positive control 
(Sengupta et al., 2003). ‘*’ p < 0.05. Values in parenthesis indicate near statistical 




of fats, and increased dietary consumption of fats correlates to an increased bile acid 
load in the intestine (Cummings et al., 1978). Although bile acids are essential for 
survival, accumulation of bile acids to high concentrations has been linked to increased 
colon tumorigenesis (Bernstein et al., 2011; Lechner et al., 2002; Pai et al., 2004).  
FXR is an adopted nuclear receptor responsible for intricately regulating free bile 
acid levels in both the liver and intestine and has been suggested to serve as a potential 
tumor suppressor for the development of colon cancer. In fact, mice deficient in FXR 
show increased colonic tumorigenesis (Maran et al., 2009; Modica et al., 2008). 
However, studies have shown that FXR anti-tumorigenic effects are at least partially 
due to bile acid independent mechanisms, namely by regulating intestinal integrity and 
inflammation (Inagaki et al., 2006; Modica et al., 2008). Identifying FXR as a potential 
tumor suppressor suggests FXR as a possible target for the prevention and/or treatment 
of human colon cancer. However, more information on FXR’s role in the development in 
human colon cancer is needed. 
In this study, we have revealed that FXR is significantly down-regulated in a 
common mouse model of intestinal carcinogenesis, APCmin  mice, which is consistent 
with previous studies (Modica et al., 2008). In addition, FXR is highly down-regulated in 
all stages of human colon cancer. Low sample number may have caused this decrease 
to lack statistical significance. However, expression of FXR target genes, OSTα and β, 
were also down-regulated suggesting that the suppression of FXR in these samples is 
indeed biologically significant. In addition, our findings are consistent with previous 
reports (De Gottardi et al., 2004). We also showed that human colon cancer cell lines 
have different expression profiles of FXR and there seems to be an inverse correlation 
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between FXR expression and malignancy of the colon cancer cell line. Sequencing of 
the FXR gene and promoter regions in colon cancer cell lines showing differences in 
FXR expression revealed no obvious mutations or SNPs that could account for the 
expression difference. Therefore, we hypothesized epigenetic modification(s) of the 
FXR gene being responsible for the difference in FXR expression seen in these colon 
cancer cell lines.  
In an initial screen, treatment of colon cancer cell lines with a clinically used 
DNMT inhibitor, AZA, resulted in an increase in FXR mRNA levels in 6 out of 11 cell 
lines tested. In confirmation of this, treatment of malignant colon cancer cell line, 
SW620 cells but not HT-29 cells, with AZA caused a corresponding increase in FXR 
mRNA levels suggesting DNA methylation of the FXR gene as the epigenetic 
mechanism involved in FXR gene silencing in human colon cancer. Sequence analysis 
revealed a putative CpG island located upstream of the FXR (NR1H4) gene which could 
serve as a potential site for DNA methylation responsible for FXR gene silencing. 
MeDIP analysis confirmed methylation of this CpG island in human colon cancer cell 
lines, HT-29 and SW620, and the more malignant cell line, SW620 cells, showed 
slightly higher levels of CpG island methylation. Bisulfite sequencing analysis was done 
to more specifically determine the methylation pattern of this CpG island and to 
associate the degree of FXR promoter methylation with decreased expression of FXR. 
We found no obvious methylation pattern within this particular island, meaning no 
specific CpG sites within this island appeared to be of particular importance for FXR 
gene suppression. However, an inverse correlation of the percentage of FXR promoter 
CpG island methylation with FXR expression in colon cancer cell lines Caco-2 and 
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SW620 was seen, but only a weak correlation detected in HT-29 cells. This could 
suggest that DNA methylation of the FXR promoter decreases FXR expression in some 
colon cancer cell lines, but not others. One observation important to point out is the lack 
of direct correlation between FXR promoter methylation to FXR mRNA levels across the 
three different colon cancer cell lines, demonstrating the involvement of other epigenetic 
mechanisms in regulating the expression of FXR. However, siRNA knockdown of DNMT 
1 and 3B both resulted in an overall increase in FXR mRNA levels in SW620 cell, 
further validating the role of DNA methylation as a mechanism of FXR silencing. 
Although these results were not found to be statistically significant, increased 
expression of the positive control gene, COL1A2, and validation by a repeat experiment 
(data not shown), confirms the biological significance of this effect. These results, thus, 
suggest that DNMT 1 and 3B are both capable of methylating FXR promoter, resulting 
in silencing of this gene. 
Clearly, DNA methylation of the FXR promoter is only partially responsible for 
regulating FXR expression in human colon cancer. Therefore, other mechanisms are 
likely also responsible. For example, over expression of histone deacetylases and 
mRNA instability have also been linked to silencing of tumor suppressor genes (Ellis et 
al., 2009; Guil and Esteller, 2009; Nelson and Weiss, 2008; Zhu et al., 2004), and these 
mechanisms may be involved in silencing FXR. Furthermore, little is known about TFs 
that regulate the expression of FXR. Therefore, it is possible that another factor 
regulates intestinal expression of FXR which is, itself, silenced by DNA methylation. 
Figure 20  illustrates our prediction of FXR silencing in human colon cancer. This study 
has demonstrated that DNA methylation of FXR promoter is, at least partially, 
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responsible for FXR silencing in colon cancer. These results correlated a high FXR 
promoter methylation to low expression of FXR, low promoter methylation to higher 
levels of FXR expression, and mixed promoter methylation partial FXR gene expression 
(Figure 20a ). Conversely, our data also predict the presence of an unknown factor(s), 
which positively regulates intestinal FXR expression under normal physiological 
processes, but is silenced in human colon cancer by promoter methylation (Figure 20b ). 
Consequently, inhibiting DNA methylation reverses the silencing of this gene, and 
therefore, restores basal expression of FXR. This scenario is consistent with our results 
showing increased FXR expression in colon cancer cell lines after inhibition of DNMT 
activity. Lastly, FXR has also been shown to be down-regulated in the acute phase 
response initiated by LPS and TNFα signaling (Savkur et al., 2005). Therefore, an 
alternative inflammatory mechanism may also be responsible for FXR down-regulation 
in human colon cancer. 
In conclusion, we confirmed FXR is down-regulated in both human colon cancer 
and mouse models of intestinal cancer. We have shown that down-regulation of FXR in 
human colon cancer is in part due to DNA methylation of the FXR promoter. Inhibition of 
FXR gene silencing, by reversing promoter methylation or other mechanisms, could 
restore basal expression of FXR in human colon cancer and, therefore, slow the 
progression of colon cancer development. This mechanism could potentially be 
exploited as a treatment and/or prevention option for human colon cancer and, therefore, 









Figure 20:   
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Figure 20: Schematic of FXR silencing in human colo n cancer.  a) FXR promoter 
methylation is in part responsible for silencing FXR expression in human colon cancer. 
Our results revealed that high percentage of promoter methylation was associated with 
lower levels of FXR expression in colon cancer cell lines (top). Conversely, low 
percentages of FXR promoter methylation was associated with elevated levels of FXR 
expression (middle). Lastly, in human colon cancer cell lines grown for 21 days, FXR 
expression either leveled off or dropped, and this was associated with a mixed or 
increased level of FXR promoter methylation (bottom). b) There is likely an unknown 
mediator of FXR transcription in the intestines. This diagram shows the unknown factor 
with a hypermethylated promoter resulting in the silencing of this gene in human colon 
cancer. The expression of this gene is necessary for the proper expression of FXR, and 
therefore, FXR expression is decreased in response to the silencing of this unknown 
factor. Conversely, inhibition of DNA methylation reverses the silencing of this factor, 
and restores its expression. There are now sufficient levels of this unknown factor is 
available to bind to the FXR promoter, or other regulatory regions, recruit transcriptional 





Chapter 7: Discussion and Conclusions  
 
7.1 General Discussion: 
 Viewing FXR as a potential therapeutic target for the treatment of several 
metabolic disorders drives the desire to better understand the physiological roles of 
FXR. Within the last two decades, research on FXR has exploded bringing to light the 
real potential for using FXR modulators to prevent and treat cholestasis, hyperlipidemia, 
type II diabetes, fatty liver, and liver and colon cancer. However, as is the case with 
therapeutically targeting other nuclear receptors, systemic activation of FXR may be 
associated with adverse health effects. Therefore, much attention is being paid to 
developing selective FXR modulators that function to enhance beneficial FXR activity, 
while minimizing undesired effects of FXR. This has guided the field towards 
understanding the epigenetic mechanisms responsible for regulating gene-specific, cell-
specific, and tissue-specific functions of FXR.  
 Epigenetics are tightly regulated molecular mechanisms capable of altering 
expression of a gene without modifying the underlying DNA sequence. Epigenetic 
mechanisms are thought to be involved in many cellular functions such as development, 
tissue-specific expression of genes, senescence, and development of diseases, such as 
cancer. More recently, epigenetics has been shown to be responsible for regulating 
nuclear receptor-mediated transcription. In fact, epigenetic mechanisms are likely 
responsible for mediating the gene-specific, cell-specific, and tissue-specific gene 
transcription of nuclear receptors, and therefore, may be a potential mechanism 
exploited for therapeutically targeting nuclear receptors for the prevention and treatment 
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of disease. However, until the recent development of genome-wide binding technology, 
understanding the role of epigenetics in regulating nuclear receptor function on a 
genome-wide scale has been lacking. This comprehensive understanding of genome-
wide nuclear receptor function is critical because of the major impact it has on 
developing selective nuclear receptor modulators. 
 FXR is a type II nuclear receptor serving as a master regulator of bile acid 
homeostasis. FXR is highly expressed in the liver and intestine and, as mentioned, has 
been shown to protect against several liver and intestinal diseases. In order to further 
determine the potential of therapeutically targeting FXR, epigenetic mechanisms 
involved in regulating the genome-wide tissue-specific functions of FXR and in 
regulating the transcription of FXR itself, needs to be further elucidated, and was the 
focus of this dissertation. The results from these studies introduced novel epigenetic 
mechanisms involved in regulating tissue-specific functions of FXR and presents DNA 
methylation of the FXR gene promoter as the epigenetic mechanism responsible for 
silencing FXR expression in human colon cancer. 
 
7.2 Overall Conclusions: 
7.2.1 Genome-wide binding of FXR in liver and intes tine. 
 As mentioned, a comprehensive genome-wide binding profile of FXR is 
necessary to begin to understand the genome-wide effects of epigenetics on FXR 
induced transcription. We began this process by performing a genome-wide binding 
assay of FXR in mouse livers and intestines after ligand treatment. This study revealed 
novel information on how FXR regulates gene transcription in a genome-wide, tissue-
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specific manner. First, this study confirmed a high degree of tissue-specific binding of 
FXR, with the liver and intestine sharing only a small percentage common FXR binding 
sites. In addition, this analysis showed novel FXR binding sites located large distances 
upstream (intergenic), downstream, or within genes (intragenic). Even though a large 
portion of FXR binding sites are located more than 10 kb away from a RefSeq gene, 
indicating long-distance chromatin looping as a possible mechanism for FXR-mediated 
regulation of gene transcription, the majority of FXR binding sites are concentrated 
within coding regions of the mouse genome. Of these sites, FXR is highly associated 
with the proximal promoter and first intron of genes.  
 Further analysis revealed novel FXR binding patterns within known and unknown 
FXR target genes. For example, FXR was shown to bind to the 5’ promoter and 3’ 
enhancer region of the Shp gene (Nr0b2). This novel binding pattern was further 
determined to form a head-to-tail chromatin loop around the Shp gene which is 
mediated by the activation of FXR (Li et al., 2010). Interestingly, this novel binding 
pattern was found within other known FXR target genes, such as Ostb and Bsep, 
suggesting FXR mediates a head-to-tail chromatin loop around these genes as well. 
Furthermore, novel FXR binding sites were found within previously uncharacterized 
target genes, including Pxr, Rarα, and Ntcp, suggesting alternative physiological roles 
of FXR in drug, steroid/hormone, and even bile acid metabolism than have not been 
previously characterized. 
Pathway analysis of FXR binding in liver and intestine revealed that FXR plays 
different physiological roles in liver and intestine. In addition, motif analysis identified a 
potential tissue-specific motif recognized by FXR. This analysis indicates the most 
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represented FXR binding motif in mouse liver is an IR-1, which has been identified in 
many FXR target genes. In mouse intestine, an IR-1 and an ER-2 motif were 
represented as possible FXR binding sequences, suggesting a possible tissue-specific 
motif recognized by FXR. In addition, there was a half nuclear receptor binding site 
adjacent to the FXR binding site in both liver and intestine. Several orphan nuclear 
receptors have been shown to bind to this particular half site suggesting a potential 
interaction between FXR and other orphan nuclear receptors/TFs to regulate tissue-
specific functions of FXR (Catalano et al., 2010; Chong et al., 2010; Ito et al., 2000; 
Wilson et al., 1992). Furthermore, the interaction between hormone nuclear receptors 
and other TFs, such as pioneer factors, have been previously reported. For example, 
ERα has been shown to interact with FOXA1 in order to initiate transcription of ER 
target genes (Lupien et al., 2008). 
In conclusion, this study analyzed the genome-wide binding of FXR in mouse 
liver and intestine after ligand treatment. The broad distribution of FXR binding, novel 
FXR binding patterns to known and unknown target genes, and the presence of a 
nuclear receptor half site associated with FXR binding, all suggest epigenetic mediators 
responsible for regulating tissue-specific functions. 
 
7.2.2 FXR and HNF4 α interact to cooperatively regulate gene transcript ion in the 
liver. 
 As has been thoroughly discussed, results from genome-wide binding analysis of 
FXR in liver and intestine suggest the involvement of orphan nuclear receptors in 
regulating FXR function. HNF4α is an orphan nuclear receptor essential for regulating 
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many liver-specific functions including development, regeneration, production of clotting 
and serum factors, lipoprotein synthesis, and drug metabolism (Gonzalez, 2008). In 
addition, HNF4α has been shown to cooperatively regulate the liver-specific functions of 
the type II nuclear receptors, PXR and CAR (Tirona et al., 2003). However, whether or 
not HNF4α regulates the liver-specific functions of FXR has not been determined. 
Therefore, the effect of HNF4α on FXR binding and transcriptional activity in mouse 
liver was assessed. 
To begin, a genome-wide binding analysis of FXR and HNF4α in mouse livers 
was done. This analysis showed a high percentage of FXR binding sites in liver co-
localized with those of HNF4α. In addition, binding frequency of HNF4α to shared target 
sites was greatest when bound upstream and in close proximity to FXR, suggesting a 
possible interaction between FXR and HNF4α, and implicating they function to co-
regulate gene transcription. Furthermore, preliminary ChIP-qPCR analysis revealed that 
binding of HNF4α to shared FXR target genes was dependent on the presence and 
activity of FXR, but FXR binding was not dependent on the presence of HNF4α. 
Likewise, co-IP assays indicate a protein-protein interaction between FXR and HNF4α, 
which is increased upon FXR activation. Finally, HNF4α was shown to transcriptionally 
regulate the FXR target gene SHP by moderately increasing FXR transcriptional activity 
of the SHP gene.  
These results revealed only a weak FXR-HNF4α interaction, and only a 
moderate cooperative effect of HNF4α on transcriptional activity of FXR. However, the 
effects of HNF4α on FXR function could be more profound than was represented in 
these assays. For example, HNF4α binding co-localized with FXR to both the 5’ 
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promoter and 3’ enhancer region of the SHP gene. As mentioned, binding of FXR to the 
5’ and 3’ region of the SHP gene mediates a head-to-tail chromatin loop around the 
SHP gene (Li et al., 2010). This may be an essential epigenetic mechanism critical for 
FXR induced transcription of the SHP gene. This same binding pattern of HNF4α to the 
SHP gene implicates that HNF4α may be critical in mediating this head-to-tail chromatin 
loop induced by FXR activation, which is a physiological mechanism not reflected in the 
assays described above.  
Nevertheless, this study ultimately confirmed a cooperative effect of FXR and 
HNF4α in mouse liver; thereby suggesting HNF4α could be an important nuclear 
receptor critical for regulating the liver-specific functions of FXR on a genome-wide 
scale. These results help progress the field focused on designing FXR modulators for 
the treatment of liver diseases. 
 
7.2.3 DNA methylation as a mechanism of FXR down-re gulation in human colon 
cancer. 
 Colon cancer is a significant public health issue in the United States. Even 
though a portion of colon cancer cases are due to heritable DNA mutations, the 
majorities of cases are sporadically derived and arise due to environmental causes. The 
western high-fat, low-fiber diets have been associated with increased colon 
tumorigenesis (Armstrong and Doll, 1975). This has been partially attributed to an 
increased exposure of colonic epithelium to bile acids. Increased fat consumption 
causes an increased intestinal load of bile acids, and low-fiber intake increases 
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gastrointestinal transit time, thereby, increasing both level and time of bile acid 
exposure (Correa, 1981; Willett et al., 1990). 
 Due to their hydrophobicity and detergent-like properties, secondary bile acids 
DCA and LCA, have been shown to increase intestinal epithelium cytotoxicity and 
promote cell proliferation, and therefore, have been linked to increased colon 
carcinogenesis (Lechner et al., 2002). However, under normal physiological conditions, 
cellular mechanisms in intestine and liver exist to increase detoxification of bile acids in 
order to prevent their accumulation to cytotoxic levels. This process, which has been 
extensively discussed, is regulated by FXR, as well as other nuclear receptors. FXR 
regulates nearly every aspect of the enterohepatic circulation of bile acids including the 
synthesis, efflux, intracellular trafficking, and enzymatic metabolism of bile acids 
(Inagaki et al., 2005; Okuwaki et al., 2007; Sinal et al., 2000; Tu et al., 2000; Zollner et 
al., 2006), and therefore, has been suggested to protect against the development of 
colon cancer. In fact, mice deficient in FXR have increased colon tumorigenesis (Maran 
et al., 2009; Modica et al., 2008). However, FXR clearly has anti-tumorigenic effects 
aside from its role in regulating bile acid levels (Inagaki et al., 2006; Modica et al., 2008). 
Ultimately, because of its anti-tumorigenic effects, FXR has become a promising 
therapeutic option for the treatment and/or prevention of colon cancer. 
 This study determined FXR expression in human colon cancers and in intestine 
of APCmin mice, a common mouse model for intestinal cancer, was decreased. Likewise, 
FXR expression in human colon cancer cell lines was inversely associated with 
malignancy of cancer cell. Sequencing of the FXR gene revealed no mutations that 
could account for differences in FXR expression or function in human colon cancer. 
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However, treating colon cancer cells with a DNMT inhibitor significantly increased FXR 
expression, suggesting DNA methylation as an epigenetic mechanism responsible for 
silencing FXR expression in colon cancer. Bisulfite sequencing and MeDIP analysis 
confirmed a CpG island located in the FXR promoter and the degree of FXR promoter 
methylation inversely correlated to expression of FXR in human colon cancer cells. 
Finally, siRNA knockdown of DNMT 1 and 3B resulted in an increase of FXR expression 
in the colon cancer cell line SW620 suggesting these enzymes are responsible for 
methylating FXR promoter, leading to decreased expression.  
 Interestingly, little is known about the role of other TFs in regulating the 
expression of FXR in the intestine. However, results from this study also suggested the 
involvement of a factor(s) that may be responsible for regulating FXR expression in the 
intestine, which is silenced by DNA methylation in human colon cancer. Nevertheless, 
more research needs to be done to further elucidate this mechanism.  
 In conclusion, this study determined that FXR is silenced in human colon cancer 
and that the epigenetic mechanism involved in FXR silencing is partially due to DNA 
methylation of the FXR promoter. Therefore, targeting FXR for treatment and/or 
prevention of colon cancer may be hindered due to selective down-regulation of FXR. 
However, reversing the silencing of FXR in human colon cancer should be further 
investigated as a potential therapeutic option for slowing the progression of colon 
cancer. 
 
7.3 Concluding Remarks : 
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 Combined, this dissertation revealed a high degree of genome-wide tissue-
specific binding of FXR proposed to be regulated by epigenetic factors, that HNF4α 
cooperatively regulates the liver-specific functions of FXR, and that DNA methylation of 
the FXR promoter is the epigenetic mechanism partially responsible for silencing FXR in 
human colon cancer. Genome-wide binding analysis predicted orphan nuclear receptors 
are responsible for regulating tissue-specific transcription of FXR target genes. HNF4α 
is an orphan nuclear receptor shown to moderately enhance FXR function in liver, and 
may be an important factor critical for regulating liver-specific function of FXR. Finally, 
FXR expression is decreased in human colon cancer and an epigenetic mechanism, 
namely DNA methylation, is responsible for the silencing of this gene. These results 
reveal novel information on the role of epigenetics in regulating FXR induced 
transcription and expression of FXR in human colon cancer, which greatly advances the 
basic knowledge needed to enhance development of selective FXR modulators for the 




Chapter 8: Future Directions 
 
 The results from my graduate research were very exciting because they have 
begun to explain epigenetic mechanisms involved in FXR regulated transcription of 
target genes and in silencing of FXR in colon cancer. However, much work is needed to 
fully characterize the intricately regulated mechanisms involved in FXR function. For this 
reason, there are several directions in which this research could be continued. 
 First, genome-wide binding analysis of FXR in this dissertation focused mainly on 
FXR expressed in mouse liver and intestine. Likewise, cooperative interactions between 
FXR and HNF4α were also investigated in mouse liver. Throughout this dissertation, I 
have extensively discussed how FXR has become a potential therapeutic target for 
treating multiple human diseases. Therefore, information obtained from FXR function in 
mice needs to be translated for understanding FXR function in humans. Although mice 
are traditionally used as models for human diseases, species differences may exist for 
FXR function. Therefore, a genome-wide binding analysis of FXR in human will be of 
great help in understanding the similarities and differences between mouse and human 
FXR function. One of the limitations for this is finding a representative human model to 
use for genome-wide binding analysis. Many genome-wide binding studies have looked 
at TFs within human cancer cell lines, which is ideal for obtaining a genetically 
homogenous cell population. One might argue, however, that cancer cells displayed 
deranged cellular function, and may not represent normal physiological functions of 
FXR. Conversely, human tissues obtained from hospital tissue banks may be a way to 
investigate normal physiological functions of FXR. However, genetic variability and 
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environmental exposure from one patient to the next would likely be an obstacle. 
Nevertheless, there is a clear need for the information gained from genome-wide 
binding analysis in mice to be translated into humans. Therefore, this is a likely future 
direction for this project. 
 Furthermore, even though FXR is highly expressed in liver and intestine, FXR is 
also expressed to a lesser extent in other tissues such as the adrenal gland, kidney, 
heart, and adipocytes (Zhang et al., 2003). However, little is known about the role FXR 
plays in these secondary tissues, although it is suggested that FXR functions to 
significantly regulate systemic metabolic parameters. As was clearly demonstrated in 
this dissertation, genome-wide binding of FXR was highly tissue-specific. It would be a 
critically important endeavor to investigate FXR’s role on a genome-wide scale within 
different systemic tissues. The information gained from this would assist in piecing 
together FXR’s systemic function within an organism as well as give insight into 
systemic off-target effects that would be associated with pharmacologically targeting 
FXR. Furthermore, it may be determined that targeting FXR for the treatment of disease 
could be extended to other tissues such as the adrenals and kidney, although FXR’s 
role in these tissues is poorly understood.  
 In addition to investigating species and tissue differences in genome-wide 
binding of FXR, more work needs to be done to elucidate the role of FXR in regulating 
gene expression of 3-dimensional chromatin. ChIP-seq of FXR unveiled some 
suggestive ideas of how FXR regulates gene expression in a 3-dimensional manner. 
However, how TF regulate 3-dimensional chromatin interactions is crucial for 
understanding regulation of gene transcription. ChIP-seq analysis identified a high 
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degree of distant FXR binding sites, but determining the function of binding to these 
regions needs to be investigated. High-through-put technology has recently been 
developed in order to capture chromatin in a 3-dimensional structure and detect long-
range chromatin interactions. This experimentation includes cross-linking nuclear 
chromatin, fragmenting chromatin by sonication, immunoprecipitating chromatin with 
antibody against TF of interest, and tethering immunoprecipitated DNA elements in 
close special distances through proximal ligation with paired-end linker tags. This is 
followed by restriction enzyme digestion and reverse-cross linking and the newly 
tethered DNA fragments are prepared for genome-wide sequencing analysis (Li et al., 
2010). This new technology is referred to as chromatin interaction analysis with paired-
end tag sequencing (ChIA-PET). This is certainly a potential direction to pursue in order 
to fully characterize the effects of FXR function in 3-dimensional genome-wide scale.  
 There is also a need to confirm and further elucidate the role of HNF4α in 
regulating FXR function in human hepatocytes. This dissertation has already described 
the effects of HNF4α on FXR function within mouse livers and in an in vitro system, and 
HNF4α was determined to have only a modest effect on FXR activity. Ideally, this 
association needs to be confirmed in vivo within human hepatocytes. However, an even 
more intriguing and pressing issue is to investigate the role of other orphan nuclear 
receptors in regulating FXR function. The reasoning behind this, in terms of targeting 
FXR function therapeutically, is that HNF4α is an extremely abundant protein within 
hepatocytes, serves many important hepatocyte-specific functions, and only appears to 
have a modest effect on FXR function. Therefore, targeting HNF4α to alter FXR function, 
or targeting HNF4α therapeutically at all, may be associated with many undesirable off-
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target effects, possibly more adverse side-effects than targeting FXR alone, and 
therefore, serves as a poor therapeutic option. However, there are likely other orphan 
nuclear receptors, whose functions are poorly understood, which serve to regulate FXR 
function. For example, as discussed above, genome-wide binding analysis revealed a 
nuclear receptor half site associated with FXRRE in mouse liver and intestine (Thomas 
et al., 2010). LRH-1 is an orphan nuclear receptor shown to bind to this half site and 
synergistically enhance transcriptional activity of FXR (Chong et al., 2010). However, 
other nuclear receptors are capable of binding this nuclear receptor half site and could 
function to regulate FXR activity (Harding et al., 1997; Harding and Lazar, 1993; Wilson 
et al., 1993; Wilson et al., 1992). Therefore, another future direction would be to 
elucidate existing orphan nuclear receptors within the liver and intestine that regulate 
FXR function. 
 Finally, I have described in this dissertation how FXR is down-regulated in 
human colon cancer, in part, by DNA methylation. Furthermore, I have extensively 
discussed how FXR deficiency in mice is associated with increased intestinal 
tumorigenesis (Maran et al., 2009; Modica et al., 2008), suggesting FXR as tumor 
suppressor. Studies have been done demonstrating activation of FXR attenuates 
intestinal symptoms in mouse models of colitis and irritable bowel disorder (Vavassori et 
al., 2009). It has been speculated that activation of FXR would also decrease intestinal 
tumorigenesis, though this has not been sufficiently studied. Therefore, a future 
direction for this project would be to test whether FXR activation by a synthetic agonist 
would decrease tumorigenesis in mouse models of intestinal cancer. I would further like 
to investigate the mechanism of how FXR decreases intestinal tumorigenesis. As 
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discussed above, FXR likely suppresses tumorigenesis via two methods, through 
preventing bile acid accumulation to toxic concentrations and by directly regulating cell 
proliferation and/or apoptosis, independent of its role in bile acid homeostasis. My goal 
would be to fully elucidate FXR’s anti-tumorigenic role. Furthermore, an ideal outcome 
for this project would be to propose FXR as a therapeutic target for chemoprevention 
and/or treatment of human colon cancer. Therefore, it is my goal to conduct a clinical 
study using an FXR agonist, whether synthetic or natural, in patients who are at high 
risk for colon cancer development, and determine the degree of FXR-induced cancer 
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